Patent Grant
11895994
This application claims the benefit of priority of China Patent Application No. 201911027061.6, filed on Oct. 27, 2019, and of Great Britain Patent Application No. 1915689.2, filed on Oct. 29, 2019, the entire contents of which are incorporated by reference herein.
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 2, 2020, is named Dehns_002_US1_SL.txt and is 68,680 bytes in size.
The present invention relates generally to genetically modified non-human animals. In particular, the present invention relates to a “knock-in” non-human animal in which a nucleotide sequence encoding an endogenous protein in the genome of the non-human animal has been replaced with a homologous human nucleotide sequence that encodes a homologous human protein. The invention also provides vectors, cells and methods for the production of such non-human animals. The invention also provides methods of testing agents for their ability to alter to the level and/or functional activity of the human protein in vivo and thus provides methods of testing agents for their potential therapeutic efficacy.
The human Protein C pathway plays a critical role in regulating coagulation (blood clotting) and inflammation. Human Protein C is activated by thrombin complexed with thrombomodulin (TM) on endothelium. Protein C is a zymogen that is converted by the thrombomodulin (TM)/Thrombin complex to Activated Protein C (APC).
Activated Protein C (APC) is a serine protease. APC cleaves activated factor V and activated factor VIII and thus negatively down-regulates thrombin formation, which is critical for maintaining the balance of thrombosis and hemostasis in vivo. Put another way, APC inhibits major driving forces of coagulation. Thus, APC has an important anticoagulant function, with APC's major targets being activated Factor V and activated Factor VIII. Human APC also contributes to the enhanced fibrinolytic response by complex formation with plasminogen activator inhibitor.
In view of its important physiological activity, protein C/APC has become an attractive therapeutic target. For example, given its important role as an anticoagulant in the regulation of clotting, Protein C/APC has been identified as a therapeutic target in the context of haemophilia (Polderdijk et al., Curr. Opin. Hematol., 2017, 24: 446-452). Haemophilia is a serious bleeding disorder, typically characterized by a deficiency or defect in factor VIII or factor IX. Treatment of haemophilia typically involves the preventative, or on-demand, administration of the missing or defective factor. Such treatments are expensive and patients undergoing such treatments can develop inhibitory antibodies to the administered factor that necessitate the use of “bypassing” agents. Alternative, and preferably improved, treatments for haemophilia are needed.
In addition to its anti-coagulant functions, APC has cytoprotective activities, including anti-inflammatory and anti-apoptotic activities, and protection of endothelial barrier function (discussed in Krisinger et al., FEBS Journal, 2009, 276:6586-6602). Thus, APC is also an attractive therapeutic target in the context of diseases characterized by inflammation and/or apoptosis. For example, APC is an attractive therapeutic target in the context of sepsis.
Although there are multiple important functions of protein C and APC, a comprehensive in vivo study of protein C and APC is still lacking. This type of in vivo study has not been possible due to the neonatal lethality of mice lacking protein C (Jalbert et al., J. Clin. Invest., 1998, 102(8): 1481-8).
Human protein C (or human APC), which is of course the relevant target in potential therapies in humans, has an amino acid sequence that is significantly different from its mouse orthologue. Mouse Protein C and human Protein C have only 69% amino acid sequence identity. This significant difference in sequence (structure) between mouse protein C and human Protein C means that studying mouse Protein C (e.g. the effects of potential therapeutic agents thereon) would not be ideal when human Protein C is the protein of interest. Furthermore, interspecies ex vivo experiments indicate that human protein C does not function efficiently in mouse plasma (discussed in Krisinger et al., FEBS Journal, 2009, 276:6586-6602).
Genetically modified non-human animals, such as mice, in which human Protein C is expressed instead of the endogenous non-human Protein C orthologue (e.g. human Protein C “knock-in” animals in which the non-human Protein C orthologue has been removed e.g. “knocked-out”) would, if they could be generated, represent very useful models for studying human Protein C in vivo, for example, for testing potential therapeutic agents that target human Protein C. However, as mice lacking Protein C (i.e. lacking mouse Protein C) are neonatal lethal and human protein C has been reported as not efficiently functioning in mouse plasma, the suggestion based on the knowledge in the art discussed above is that the provision of such a genetically modified animal, e.g. a mouse, would not be possible.
However, surprisingly, the present inventors have been able to generate such genetically modified mice. These mice are viable, appear healthy and have bleeding characteristics that are in line with the bleeding characteristics of relevant control mice that express endogenous mouse Protein C and not human Protein C.
Thus, in a first aspect, the present invention provides a genetically modified non-human animal, in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
In some embodiments, the non-human animal is a non-human mammal. In some embodiments, the non-human animal is a rodent. In some embodiments, the non-human animal is a mouse or a rat, preferably a laboratory mouse or rat.
A preferred non-human animal in accordance with the invention is a mouse. Preferably, the mouse is a laboratory mouse. A particularly preferred strain of mouse is C57BL/6.
The non-human animals of the present invention are genetically modified. This of course means that these animals are not naturally occurring animals, i.e. are not native or wildtype animals. The genetic modification is established by technical means, e.g. as described elsewhere herein. In accordance with the present invention, the genetic modification includes the replacement of at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
Non-human animals of the invention express, or are capable of expressing, human Protein C, a functional fragment of human Protein C or a functional variant of human Protein C.
An endogenous nucleotide sequence encoding Protein C means a nucleotide sequence that encodes Protein C that is wildtype (or native or endogenous) to the non-human animal.
The coding sequence (CDS) of endogenous Protein C is the nucleotide sequence that encodes (or corresponds to) the sequence of amino acids in Protein C protein. The CDS starts with a start codon (typically ATG) and ends with a stop codon (e.g. TAG). However, as the skilled person is aware, in the context of an endogenous animal gene (i.e. in a genomic context) the coding sequence of Protein C (which is present in exons) is typically interrupted by introns, meaning that, in the endogenous gene itself, the CDS is present as a discontinuous sequence of nucleotides.
Thus, in preferred embodiments of the present invention, the endogenous nucleotide sequence encoding Protein C that has been replaced is all or part of the nucleotide sequence that begins at the start codon and ends at the stop codon, including other exon sequences and intron sequences between the start codon and the stop codon. In preferred embodiments, the entire (i.e. all of) nucleotide sequence from the start codon to the stop codon, including other exon sequences and intron sequences between the start codon and the stop codon, has been replaced.
As indicated above, a mouse is a particularly preferred non-human animal in accordance with the invention. Mouse Protein C means Protein C that is wildtype (or native) to a mouse. The amino acid sequence of mouse Protein C is set forth herein as SEQ ID NO:12. A nucleotide coding sequence (CDS) of mouse Protein C is set forth herein as SEQ ID NO:10. The mouse Protein C (Proc) gene (NCBI Reference Sequence: NM_001042767.3) is located on mouse chromosome 18. Nine exons have been identified, with the start codon (ATG) located in exon 2 and the stop codon (TAG) located in exon 9.
Thus, in preferred embodiments of the present invention, the endogenous nucleotide sequence encoding mouse Protein C that has been replaced is all or part of the nucleotide sequence from the start codon (ATG) in exon 2 of the mouse Protein C gene to the stop codon in exon 9 of the mouse Protein C gene, including other exon sequences and intron sequences between the start codon and the stop codon. In preferred embodiments, the entire (i.e. all of) the nucleotide sequence from the start codon (ATG) in exon 2 of the mouse Protein C gene to the stop codon in exon 9 of the mouse Protein C gene, including other exon sequences and intron sequences between the start codon and the stop codon, is replaced.
As a result of the replacement of at least one copy of an endogenous nucleotide sequence encoding Protein C in accordance with the present invention, at least one allele of the Protein C gene in the non-human animal does not encode Protein C that is wildtype (or native) for that animal. Accordingly, at least one allele of the Protein C gene in the non-human animal does not express (and is not capable of expressing) an mRNA encoding Protein C that is wildtype (or native) for that animal.
In the case of mice, at least one allele of the Protein C gene in a genetically modified mouse of the invention does not encode Protein C that is wildtype (or native or endogenous) for the mouse. Accordingly, at least one allele of the Protein C gene in the mouse does not express an mRNA molecule encoding Protein C that is wildtype (or native) for the mouse, e.g. an mRNA molecule encoding SEQ ID NO:12 (e.g. an mRNA having a nucleotide sequence that corresponds to SEQ ID NO:10).
Human Protein C means Protein C that is a wild-type (or native or endogenous) to a human. The amino acid sequence of human Protein C is set forth herein as SEQ ID NO:11. A nucleotide coding sequence (CDS) of human Protein C is set forth herein as SEQ ID NO:8. In the context of the present invention, a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C may be considered a heterologous (or foreign or exogenous) nucleotide sequence.
Preferably, at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal has been replaced by a nucleotide sequence encoding human Protein C (i.e. full-length or wildtype human Protein C). Thus, preferably, at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal has been replaced by a nucleotide sequence encoding human Protein C, wherein human Protein C comprises (or consists of) the amino acid sequence of SEQ ID NO:11. An exemplary and preferred nucleotide sequence encoding human Protein C (SEQ ID NO:11) is set forth in SEQ ID NO:8. The nucleotide sequence encoding human Protein C may alternatively comprise (or consist of) a sequence substantially homologous to SEQ ID NO: 8, e.g. a codon degenerate version of SEQ ID NO:8.
Typically and preferably, the nucleotide sequence encoding human Protein C is the coding sequence (CDS) of the human Protein C gene, i.e. excluding introns and untranslated regions UTRs of the human Protein C gene.
In alternative embodiments, the nucleotide sequence encoding human Protein C may additionally comprise intron sequences of the human Protein C gene. In some embodiments, human 5′ UTR and/or human 3′ UTR nucleotide sequences may additionally be provided. The human Protein C (PROC) gene (NCBI Reference Sequence: NM_000312.3) is located on human chromosome 2. Nine exons have been identified, with the start codon (ATG) in exon 2 and the stop codon (TAG) in exon 9.
In some alternative embodiments, at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal has been replaced by a nucleotide sequence encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C (i.e. instead of full-length wildtype human Protein C).
A “functional” fragment of human Protein C or a “functional” variant of human Protein C means a fragment or variant that exhibits (or maintains) at least one functional activity of the full-length wildtype human Protein C, e.g. exhibits at least 10%, at least 25%, at least 75%, at least 90% or at least 100% of the level of at least one functional activity of the full-length wildtype human Protein C. The functional activity may be, for example, anticoagulant activity and/or cytoprotective activity (e.g. anti-inflammatory activity and/or anti-apoptotic activity), e.g. as described elsewhere herein.
In some embodiments, a fragment of human Protein C can be at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 consecutive amino acids in length. In some embodiments, fragments can be up to 460 consecutive amino acids in length (e.g. 100-460, 200-460, 300-460, or 400-460 consecutive amino acids in length).
In some embodiments, a fragment of human Protein C is a naturally occurring fragment of human Protein C, for example Activated Protein C (APC).
In some embodiments, a variant of human Protein C is a protein having an amino acid sequence that is substantially homologous to the amino acid sequence of full-length wildtype human Protein C (or a fragment thereof).
The term “substantially homologous” as used herein in connection with an amino acid or nucleic acid sequence includes sequences having at least 75%, at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, sequence identity to the amino acid or nucleic acid sequence disclosed. Substantially homologous sequences of the invention thus include single or multiple base or amino acid alterations (additions, substitutions, insertions or deletions) to the sequences of the invention. At the amino acid level preferred substantially homologous sequences contain up to 10 or up to 5, e.g. only 1, 2, 3, 4 or 5, preferably 1, 2 or 3, more preferably 1 or 2, altered amino acids. Said alterations can be with conservative or non-conservative amino acids. Preferably, said alterations are conservative amino acid substitutions.
A “conservative amino acid substitution”, as used herein, is one in which the amino acid residue is replaced with another amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g. lysine, arginine, histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g. glycine, cysteine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g. tyrosine, phenylalanine, tryptophan, histidine).
Methods of carrying out manipulation of amino acids and protein domains (e.g. to generate substantially homologous sequences) are well known to a person skilled in the art. For example, said manipulations could conveniently be carried out by genetic engineering at the nucleic acid level wherein nucleic acid molecules encoding appropriate proteins are modified such that the amino acid sequence of the resulting expressed protein is in turn modified in the appropriate way.
Variants of human Protein C (or fragments thereof) also include modified versions of human Protein C (or fragments thereof) such as human Protein C (or fragments thereof) that contain one or more additional amino acids at one or both termini (e.g. contain one or more N-terminal and/or C-terminal fusion moiety or fusion tag or epitope tag). Thus, variants may include fusion proteins comprising the amino acid sequence of human Protein C (or a fragment of human Protein C).
Determining the degree of homology between sequences may be assessed by any convenient method. However, for determining the degree of homology between sequences, computer programs that make multiple alignments of sequences are useful, for instance Clustal W (Thompson, Higgins, Gibson, Nucleic Acids Res., 22:4673-4680, 1994). If desired, the Clustal W algorithm can be used together with BLOSUM 62 scoring matrix (Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA, 89:10915-10919, 1992) and a gap opening penalty of 10 and gap extension penalty of 0.1, so that the highest order match is obtained between two sequences wherein at least 50% of the total length of one of the sequences is involved in the alignment. Other methods that may be used to align sequences are the alignment method of Needleman and Wunsch (Needleman and Wunsch, J. Mol. Biol., 48:443, 1970) as revised by Smith and Waterman (Smith and Waterman, Adv. Appl. Math., 2:482, 1981) so that the highest order match is obtained between the two sequences and the number of identical amino acids is determined between the two sequences. Other methods to calculate the percentage identity between two amino acid sequences are generally art recognized and include, for example, those described by Carillo and Lipton (Carillo and Lipton, SIAM J. Applied Math., 48:1073, 1988) and those described in Computational Molecular Biology, Lesk, ed. Oxford University Press, New York, 1988, Biocomputing: Informatics and Genomics Projects.
Generally, computer programs will be employed for such calculations. Programs that compare and align pairs of sequences, like ALIGN (Myers and Miller, CABIOS, 4:11-17, 1988), FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85:2444-2448, 1988; Pearson, Methods in Enzymology, 183:63-98, 1990) and gapped BLAST (Altschul et al., Nucleic Acids Res., 25:3389-3402, 1997), BLASTP, BLASTN, or GCG (Devereux, Haeberli, Smithies, Nucleic Acids Res., 12:387, 1984) are also useful for this purpose. Furthermore, the Dali server at the European Bioinformatics institute offers structure-based alignments of protein sequences (Holm, Trends in Biochemical Sciences, 20:478-480, 1995; Holm, J. Mol. Biol., 233:123-38, 1993; Holm, Nucleic Acid Res., 26:316-9, 1998).
By way of providing a reference point, sequences according to the present invention having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology, sequence identity etc. may be determined using the ALIGN program with default parameters (for instance available on Internet at the GENESTREAM network server, IGH, Montpellier, France).
In accordance with the present invention, at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
Typically, non-human animals of the present invention are diploid animals, meaning that their somatic cells contain two homologous copies (or homologues) of each chromosome. In normal (unmodified or wildtype) diploid animals, one endogenous copy of the Protein C gene is found on each of the two chromosomes in the relevant chromosome pair. For example, in normal (wildtype) mice, the Protein C gene is encoded on chromosome 18, so in normal mouse somatic cells there will be two copies of the mouse Protein C gene, one on each chromosome 18.
In some embodiments, one copy of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in some embodiments, the genetically modified non-human animal is heterozygous for a human Protein C allele in accordance with the invention. Such heterozygotes may be conveniently referred to as being hproC+/−.
In preferred embodiments, both (i.e. two) copies of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal have been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in preferred embodiments, the genetically modified non-human animal is homozygous for a human Protein C allele in accordance with the invention. Such homozygotes may be conveniently referred to as being hproC+/+. For the avoidance of doubt, such homozygote animals do not comprise in their genome a nucleotide sequence encoding Protein C that is wildtype (or native) for that animal.
In a particularly preferred embodiment, the invention provides a genetically modified mouse, in which both copies of the endogenous nucleotide sequence encoding Protein C in the genome of said mouse have been replaced by a nucleotide sequence encoding human Protein C.
References herein to “a human Protein C allele” or to a “human Protein C allele in accordance with the invention” are used as shorthand for an allele in which an endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
References herein to “at least one copy” or “at least one allele” (or similar) typically means one or two copies or one or two alleles, preferably two copies or two alleles (or both copies or both alleles).
Nucleotide sequences encoding Protein C as discussed herein are of course nucleotide sequences in nucleic acid molecules. Thus, they may be considered nucleic acid molecules (typically DNA molecules) comprising (or consisting of) a described nucleotide sequence.
References herein to the “genome” of a genetically modified non-human animal are typically references to the genome of somatic cells (or diploid cells) of a non-human animal of the invention. Of course, a human Protein C allele in accordance with the invention may also be present in the genome (haploid genome) of some, or all (or substantially all), germ cells (eggs or sperm) of a genetically modified animal of the invention.
“Replaced by” in the context of the present invention means that an endogenous (or wildtype or native) Protein C allele in the genome of the non-human animal has been modified such that rather than comprising (and thus encoding) an endogenous nucleotide sequence encoding endogenous Protein C, the allele instead comprises a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof). Thus, an endogenous nucleotide sequence encoding endogenous Protein C has been removed and a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is present in its place. Preferably both Protein C alleles have been so modified.
In preferred embodiments, the start codon (e.g. ATG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the Protein C gene in the genome of the non-human animal at the position corresponding to the start codon of the nucleotide sequence encoding endogenous Protein C and the stop codon (e.g. TAG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the Protein C gene in the genome of the non-human animal at the position corresponding to the stop codon of the nucleotide sequence encoding endogenous Protein C.
In some preferred genetically modified mice of the invention, the start codon (e.g. ATG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the Protein C gene of the mouse at the position corresponding to the start codon (ATG) in exon 2 of the mouse Protein C gene, and the stop codon (e.g. TAG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the Protein C gene in the mouse at the position corresponding to the stop codon (TAG) in exon 9 of the mouse Protein C gene.
The start codon (ATG) in exon 2 of the mouse Protein C gene (endogenous or wildtype mouse Protein C gene) is positioned immediately following (i.e. immediately 3′ to or immediately downstream of) the 5′-UTR (untranslated region) portion of exon 2. The stop codon (TAG) in exon 9 of the mouse Protein C gene (endogenous or wildtype mouse Protein C gene) is positioned immediately in front of (i.e. immediately 5′ to or immediately upstream of) the 3′-UTR (untranslated region) portion of exon 9.
Thus, in some preferred embodiments of a genetically modified mouse of the invention, the start codon (e.g. ATG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the mouse genome immediately following (i.e. immediately 3′ to or immediately downstream of) the 5′-UTR (untranslated region) portion of exon 2, and the stop codon (e.g. TAG) of the nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) is positioned (or located or inserted) in the mouse genome immediately in front of (i.e. immediately 5′ to or immediately upstream of) the 3′-UTR (untranslated region) portion of exon 9. A nucleotide sequence of the 5′-UTR (untranslated region) portion of exon 2 of the mouse Protein C gene is set forth herein as SEQ ID NO:5. A nucleotide sequence of the 3′-UTR (untranslated region) portion of exon 9 of the mouse Protein C gene is set forth herein as SEQ ID NO:6.
Alternatively viewed, an endogenous nucleotide sequence encoding endogenous Protein C in the genome of a non-human animal (e.g. mouse) has been substituted with a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof). Preferably, both Protein C alleles have been so substituted.
Alternatively viewed, the non-human animal of the invention (e.g. mouse) contains a targeted insertion of a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof) into at least one copy of the Protein C gene in the animal, wherein, as a result of the targeted insertion, said at least one copy of the Protein C gene comprises (and is capable of expressing) a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) and does not comprise (and thus is not capable of expressing) an endogenous (or wildtype or native) nucleotide sequence encoding endogenous Protein C. Preferably, both copies of the Protein C gene in the genome of the non-human animal have the targeted insertion.
Alternatively viewed, the non-human animal of the invention (e.g. mouse) is characterised by a targeted replacement of a nucleotide sequence encoding endogenous Protein C in the genome of said non-human animal by a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof). Preferably, the non-human animal of the invention comprises such a targeted replacement in both Protein C alleles in its genome.
Such a modified allele may be referred to as a “knock-in” allele (or KI allele). In this regard, a nucleotide sequence encoding human Protein C (or encoding a functional fragment or functional variant thereof) is “knocked-in” to at least one Protein C allele in the genome a non-human animal. Such a “knock-in” results in the removal of the endogenous nucleotide sequence encoding endogenous Protein C. Thus, the modified (knock-in) allele has the endogenous nucleotide sequence encoding endogenous Protein C knocked-out. Accordingly, an endogenous nucleotide sequence encoding endogenous Protein C is replaced by a nucleotide sequence encoding human Protein C (or functional fragment functional variant thereof). In preferred embodiments, a “knock-in” allele in accordance with the invention is a constitutive knock-in allele.
Determining whether or not at least one copy (e.g. one copy or two copies) of the endogenous nucleotide sequence encoding Protein C in the genome of a non-human animal has been replaced by a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof) in a given non-human animal can be done by any appropriate means and suitable methods are well-known to a skilled person. For example, genotyping could be used, e.g. a PCR-based genotyping method and/or Southern blotting could be used. Suitable methods are described in the Example section herein.
In some embodiments, the non-human animals of the invention are produced using a method that employs a vector of the invention.
Thus, in some embodiments, a non-human animal in accordance with the invention comprises in its genome at least one allele of the Protein C gene that comprises (i) a 5′ untranslated region (UTR) nucleotide sequence of the non-human animal Protein C gene, (ii) a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof) and (iii) a 3′ untranslated region (UTR) nucleotide sequence of the non-human animal Protein C gene. Elements (i), (ii) and (iii) are typically positioned immediately after each other in this order (i.e. (i) followed immediately by (ii) followed immediately by (iii)), in the 5′ to 3′ direction. In some embodiments, a marker for positive selection may be positioned 5′ with respect to the 5′-UTR or be positioned 3′ with respect to the 3′ UTR. The marker for positive selection may be flanked by site-specific recombination sites (e.g. LoxP sites). In some embodiments, the marker for positive selection may have been removed (e.g. by a site-specific recombinase enzyme such as Cre recombinase). In embodiments in which the marker for positive selection has been removed by a site-specific recombinase enzyme (such as Cre), the nucleotide sequence of a single site-specific recombination site is typically retained in the allele.
In some embodiments, a non-human animal in accordance with the invention is a mouse that comprises in its genome at least one allele of Protein C gene that comprises (i) a 5′ untranslated region (UTR) nucleotide sequence of exon 2 of the mouse Protein C gene (e.g. SEQ ID NO:5), (ii) a nucleotide sequence encoding human Protein C and (iii) a 3′ untranslated region (UTR) nucleotide sequence of exon 9 of the mouse Protein C gene (e.g. SEQ ID NO:6). Elements (i), (ii) and (iii) are typically positioned immediately after each other in this order (i.e. (i) followed immediately by (ii) followed immediately by (iii)), in the 5′ to 3′ direction. In some embodiments, a marker for positive selection (e.g. Neo′) may be positioned 5′ with respect to the 5′-UTR or be positioned 3′ with respect to the 3′ UTR, preferably positioned 3′ with respect to the 3′ UTR. The marker for positive selection may be flanked by site-specific recombination sites (e.g. LoxP sites). A preferred such allele is substantially as depicted in
In preferred embodiments, the only substantive modification to a Protein C allele (or protein C gene) in the non-human animal (i.e. modification as compared to the wildtype Protein allele in the relevant non-human animal) is the replacement of (or substitution of) an endogenous nucleotide sequence encoding Protein C by a nucleotide sequence encoding human Protein C (or functional fragment or functional variant thereof). The presence of a marker for positive selection marker and/or one or more site-specific recombination sites would not be typically considered substantive modifications.
Thus, in preferred embodiments, human Protein C alleles in accordance with the invention comprise sequences upstream (5′- to) and downstream (3′-) to the nucleotide sequence encoding human Protein C (or functional fragment or functional variant thereof) that are wildtype (or native or endogenous) for the relevant non-human animal. Such sequences may include regulatory sequences, such as promoters and/or enhancers, etc. Thus, in preferred embodiments, expression of the nucleotide sequence encoding human Protein C (or functional fragment or functional variant thereof) is under the control of the endogenous regulatory sequences of the Protein C gene of the relevant non-human animal.
In some alternative embodiments, a human Protein C allele in accordance with the invention may additionally comprise one or more regulatory sequences (e.g. promoters and/or enhancers) of the human Protein C gene (e.g. to replace one or more regulatory sequences of the non-human animal).
In some embodiments, a genetically modified non-human animal of the invention further comprises one or more additional genetic modifications in its genome (i.e. additional to the replacement of an endogenous nucleotide sequence encoding Protein C by a nucleotide sequence encoding human Protein C or fragment or variant thereof). The skilled person is familiar with methods for making such genetic modifications, e.g. gene knock-outs.
In some such embodiments, the further genetic modification is a modification that down-regulates or inactivates (or renders the animal deficient in or devoid of) of one or more other (i.e. non-Protein C) genes. For example, the further genetic modification may be a knock-out of one or more other genes.
In some embodiments, the other gene is a gene encoding a blood clotting factor (e.g. one or more blood clotting factors may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor VIII (e.g. Factor VIII may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor IX (e.g. Factor IX may additionally be knocked-out). In some embodiments, there may be further genetic modifications in the genes encoding Factor VIII and Factor IX (e.g. Factor VIII and Factor IX may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor X (e.g. Factor X may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor XI (e.g. Factor XI may additionally be knocked-out).
In some embodiments, a non-human animal of the invention is an experimental non-human animal model (e.g. mouse model). Such experimental animal models are typically suitable for studying human Protein C in vivo. In particular, such experimental animal models are typically suitable for testing agents (e.g. candidate therapeutic agents) to identify the potential for the use of such agents in therapy (e.g. human therapy), In some embodiments, the therapy (or potential therapy) is therapy (or potential therapy) of a disease or condition associated with Protein C or APC (or the Protein C or APC pathway), e.g. as discussed elsewhere herein.
Non-human animals at each stage of development, e.g. embryonic, juvenile, or adult, are encompassed by the present invention. In some embodiments, the non-human animals are adult animals. In the case of mice, in some embodiments the mice are at least six weeks of age, preferably at least 8 weeks of age (e.g. 8-10 weeks of age).
Alternatively viewed, or in another aspect, the present invention provides a genetically modified non-human animal (e.g. a mouse) comprising in its genome at least one nucleic acid molecule encoding human Protein C (or a functional fragment or functional variant thereof), wherein said nucleic acid molecule is located in (and capable of being expressed from) the Protein C gene of the genetically modified non-human animal. Preferably, said at least one nucleic acid molecule is operably linked in the genome of the non-human animal to one or more of the regulatory elements (e.g. promoters and/or enhancers) of the Protein C gene in the non-human animal (endogenous regulatory elements). Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Alternatively viewed, or in another aspect, the present invention provides a genetically modified non-human animal (e.g. mouse) having a modified Protein C gene locus, said modified Protein C locus being characterised by the presence of a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof) and the absence of a nucleotide sequence encoding Protein C that is endogenous to the non-human animal. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Further alternatively viewed, or in another aspect, the present invention provides a knock-in non-human animal (e.g. mouse), wherein a nucleic acid molecule comprising a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof) is knocked-in to one or more copies of the Protein C gene in the genome of the non-human animal. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Further alternatively viewed, or in another aspect, the present invention provides a humanized non-human animal (e.g. mouse) comprising in its genome at least one humanized Protein C allele, said humanized Protein C allele being characterized in that the endogenous nucleotide sequence encoding endogenous Protein C has been replaced by a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof). Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Further alternatively viewed, or in another aspect, the present invention provides a transgenic non-human animal (e.g. mouse), in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal has been replaced by a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof). Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Further alternatively viewed, or in another aspect, the present invention provides a genetically modified non-human animal (e.g. mouse), comprising in its genome a nucleotide sequence that encodes human Protein C (or a fragment or variant thereof), wherein said nucleotide sequence is operably linked to an endogenous Protein C regulatory sequence (e.g. promoter) at the non-human animal Protein C locus. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Further alternatively viewed, or in another aspect, the present invention provides a genetically modified non-human animal (e.g. mouse) carrying (or comprising) a heritable exchange in a nucleotide sequence, said exchange being the replacement of (or exchange of or substitution of) an endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal by a nucleotide sequence encoding human Protein C (or a functional fragment or a functional variant thereof). In accordance with the discussion elsewhere herein, said heritable exchange is established by technical means. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a genetically modified non-human animal (e.g. a mouse), wherein said animal comprises in its genome (e.g. stably integrated into its genome), and is capable of expressing, one or more (e.g. one or two) copies of a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof). Preferably, such animals do not encode (and thus are not capable of expressing) endogenous Protein C. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention. For example, said nucleotide sequence may be positioned in the Protein C gene of the non-human animal (e.g. to replace a nucleotide sequence encoding endogenous Protein C in the non-human animal), for example as described elsewhere herein.
In another aspect, the present invention provides a genetically modified non-human animal (e.g. a mouse), wherein said animal expresses (or is capable of expressing) human Protein C (or a functional fragment or functional variant thereof) and does not express (or is not capable of expressing) endogenous Protein C (i.e. does not express (or is not capable of expressing) Protein C that is wildtype or native to the non-human animal species). Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
Typically, a non-human animal of the invention is fertile and capable of transmitting a human Protein C allele in accordance with the invention to its offspring.
Thus, in one aspect, the present invention provides offspring or descendants of a non-human animal of the invention, wherein said offspring or descendants comprise in their genome at least one (preferably two) human Protein C allele(s) in accordance with the invention. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a cell or cell line derived from a genetically-modified non-human animal of the invention, wherein said cell or cell line comprises in its genome at least one (preferably two) human Protein C allele(s) in accordance with the invention. The cell may be a somatic cell or a germ cell. In some embodiments, the cell or cell line is a pluripotent stem cell or cell line (e.g. an embryonic stem cell or cell line derived from an embryonic non-human animal of the invention or an induced pluripotent stem cell (iPSC)), or a cell line derived from a somatic cell of a non-human animal of the invention. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a tissue or organ derived from a genetically-modified non-human animal of the invention, wherein said tissue or organ comprises in the genome of the cells thereof at least one (preferably two) human Protein C allele(s) in accordance with the invention. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a cell-containing sample derived from a genetically-modified non-human animal of the invention, wherein said sample comprises in the genome of the cells thereof at least one (preferably two) human Protein C allele(s) in accordance with the invention. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a non-human (e.g. mouse) pluripotent stem cell in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention. The non-human pluripotent stem cell may be, for example, an embryonic stem (ES) cell or an induced pluripotent stem cell (iPSC). Embryonic stem (ES) cells are preferred. Preferably, the non-human pluripotent stem cell is a mouse pluripotent stem cell, such as a mouse embryonic stem (ES) cell or a mouse induced pluripotent stem cell (iPSC). Mouse embryonic stem (ES) cells are particularly preferred (for example C57BL/6 ES cells).
In another aspect, the present invention also provides a vector for homologous recombination in a non-human pluripotent stem cell (e.g an isolated non-human pluripotent stem cell), wherein said vector is capable of replacing (or conferring the replacement of or mediating the replacement of) at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent stem cell with a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof).
A vector of the invention may also be considered a targeting vector (or a gene targeting vector), a recombinant vector or a recombinant targeting vector. The vector is a nucleic acid molecule, preferably a DNA molecule.
Preferably, the non-human pluripotent stem cells are of a species of non-human animal described elsewhere herein. In some embodiments, the non-human pluripotent stem cells are non-human embryonic stem (ES) cells. Preferably, the non-human pluripotent stem cells are mouse pluripotent stem cells. Particularly preferably, the non-human pluripotent stem cells are mouse embryonic stem (ES) cells. In some embodiments, the mouse embryonic stem (ES) cells are C57BL/6 ES cells.
In one aspect, and in some embodiments, the invention provides a vector comprising, in functional combination, (i) a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C (preferably a nucleotide sequence encoding human Protein C); (ii) at least one marker for positive selection (e.g. an antibiotic resistance gene such as the neomycin resistance gene, Neo′); (iii) a 5′-homology arm; and (iv) a 3′-homology arm.
In some embodiments, the marker for positive selection is flanked by site-specific recombination sites (e.g. loxP sites) that can be recognised by a recombinase enzyme (e.g. Cre recombinase).
In some embodiments, the marker for positive selection (and its flanking site-specific recombination sites where present) is positioned within one of the homology arms. Put another way, in some embodiments one of the homology arms in the vector is interrupted by the marker for positive selection (and its flanking site-specific recombination sites where present). Thus, in some embodiments, one of the homology arms (e.g. the 3′-homology arm) comprises two distinct parts (or sub-parts) with the marker for positive selection (and its flanking site-specific recombination sites where present) being located between said two parts.
In some embodiments, at least one marker for negative selection is additionally present in the vector (e.g. a gene encoding a toxin such as diptheria toxin A, DTA, or a gene encoding thymidine kinase).
In a preferred embodiment, the vector of invention comprises, in order from 5′ to 3′, (i) a 5′-homology arm, (ii) a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C (preferably a nucleotide sequence encoding human Protein C); (iii) a 3′-homology arm and (iv) a marker for positive selection (optionally flanked by site-specific recombination sites where present), wherein the marker for positive selection (and its flanking site-specific recombination sites where present) is positioned within the 3′ homology arm. In some such embodiments, a marker for negative selection is additionally present in the vector and is positioned 5′ with respect to the 5-homology arm (i.e. it is positioned 5′ of the 5′ end of the 5-homology arm).
A homology arm (a 5′- or 3′-homology arm) is a portion (or fragment or segment) of DNA having a nucleotide sequence that corresponds to (or corresponds essentially to) a nucleotide sequence in the genome of the relevant (or corresponding) non-human animal cell to be targeted. Alternatively viewed, a homology arm is a polynucleotide having a nucleotide sequence that corresponds to (or corresponds essentially to) a nucleotide sequence in the genome of the relevant (or corresponding) non-human cell to be targeted. In some embodiments, a homology arm is a portion of DNA having a nucleotide sequence that corresponds to or corresponds essentially to (e.g. has at least 90%, or at least 95%, or at least 99%, preferably 100% identity to) a nucleotide sequence in the genome of the relevant (or corresponding) non-human cell to be targeted.
Homology arms are of sufficient length to be able to confer (or mediate) homologous recombination between the vector and the corresponding nucleotide sequence (or target cognate chromosomal region) in the genome of the non-human animal cell to be targeted. Each homology arm is typically at least 500 base pairs in length, preferably at least 1,000, at least 2,000, at least 3,000, at least 4,000, at least 5,000, at least 6,000, at least 7,000, at least 8,000, at least 9,000 or at least 10,000 base pairs in length (e.g. 1,000 to 10,000 base pairs in length). The 5′-homology arm and the 3′-homology arm are not necessarily the same length.
After introduction into the non-human animal cell, the homology arms can undergo homologous recombination with the corresponding (or target) genomic DNA sequences in the non-human cell to achieve genetic modification (or targeting) of the chromosomal locus. In accordance with the present invention, the chromosomal locus is the Protein C gene and the genetic modification is the replacement of an endogenous nucleotide sequence encoding Protein C in the genome of the non-human cell with a nucleotide sequence encoding human Protein C (or encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C).
Thus, homology arms in accordance with the present invention typically comprise (or consist of) nucleotide sequences that can undergo homologous recombination with corresponding genomic nucleotide sequences of the endogenous Protein C gene (or Protein C locus) in a non-human pluripotent stem cell to achieve targeted replacement of an endogenous nucleotide sequence encoding endogenous Protein C in the genome of the non-human pluripotent stem cell with a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof).
A 5′-homology arm comprises (or consists of or consists essentially of) a nucleotide sequence that corresponds to or corresponds essentially to (e.g. has at least 90%, or at least 95%, or at least 99%, preferably 100% identity to) a genomic sequence in the non-human animal that is positioned 5′ with respect to the endogenous nucleotide sequence encoding Protein C. Thus, typically, a 5′-homology arm is, after introduction of the vector into a non-human animal cell, capable of undergoing (or capable of mediating) homologous recombination with the corresponding (or target) genomic DNA sequence in the genome of the non-human animal that is positioned 5′ to nucleotide sequence encoding Protein C.
A 3′-homology arm comprises (or consists of or consists essentially of) a nucleotide sequence that corresponds to or corresponds essentially to (e.g. has at least 90%, or at least 95%, or at least 99%, preferably 100% identity to) a genomic sequence in the non-human animal that is positioned 3′ with respect to the endogenous nucleotide sequence encoding Protein C. Thus, typically, a 3′-homology arm is, after introduction of the vector into the non-human animal cell, capable of undergoing (or capable of mediating) homologous recombination with the corresponding (or target) genomic DNA sequence in the genome of the non-human animal that is positioned 3′ to the nucleotide sequence encoding Protein C.
The skilled person in this field is familiar with homology arms and would be readily able to identify and select appropriate homology arms for inclusion in vectors of the invention. For example, genomic fragments containing homology arms could be amplified (e.g. using a high fidelity Taq DNA polymerase) from a BAC (bacterial artificial chromosome) clone containing the desired genomic sequence of the relevant non-human animal. BAC clones and libraries are commercially available.
In some embodiments, the 5′-homology arm of a vector of the invention comprises (or consists of) a nucleotide sequence of SEQ ID NO:2, or a sequence substantially homologous thereto (e.g. a sequence having at least 90%, at least 95 or at least 99% sequence identity to SEQ ID NO:2). A 5′-homology arm consisting of a nucleotide sequence of SEQ ID NO:2 is preferred.
In some embodiments, the 3′-homology arm of a vector of the invention comprises a nucleotide sequence of SEQ ID NO:3 and/or a nucleotide sequence of SEQ ID NO:4, or a sequence substantially homologous to SEQ ID NO:3 and/or substantially homologous to SEQ ID NO:4 (e.g. a sequence having at least 90%, at least 95 or at least 99% sequence identity to SEQ ID NO:3 and/or substantially homologous to SEQ ID NO:4). In some embodiments, the 3′-homology arm of a vector of the invention comprises a nucleotide sequence of SEQ ID NO:3 and a nucleotide sequence of SEQ ID NO:4, or a sequence substantially homologous to SEQ ID NO:3 and/or SEQ ID NO:4. In some embodiments, a 3′-homology arm comprising a nucleotide sequence of SEQ ID NO:3 and SEQ ID NO:4 is preferred.
In some embodiments, the 3′-homology arm comprises a nucleotide sequence of SEQ ID NO:3 (or substantially homologous sequence) and a nucleotide sequence of SEQ ID NO:4 (or substantially homologous sequence), wherein the nucleotide sequences of SEQ ID NO:3 (or substantially homologous sequence) and SEQ ID NO:4 (or substantially homologous sequence) are separated by a nucleotide sequence encoding a marker for positive selection (which is optionally flanked by site-specific recombination sites).
As indicated above, the vector comprises a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Preferably, the vector comprises a nucleotide sequence encoding human Protein C. The amino acid sequence of human Protein C is set forth herein as SEQ ID NO:11. Thus, preferably, the vector comprises a nucleotide sequence encoding SEQ ID NO:11. A preferred nucleotide sequence encoding human Protein C (SEQ ID NO:11) is SEQ IS NO:8.
As indicated above, vectors of the invention may comprise a marker for positive selection. A marker for positive selection is typically a nucleotide sequence encoding a protein that confers antibiotic resistance upon a cell in which it is expressed. The positive selection marker enables the selection (or identification) of cells into which the vector has been transfected and which are expressing the vector. The marker for positive selection is typically an antibiotic resistance gene. The neomycin resistance gene (Ned, Neo cassette) is a preferred positive selection marker. The neomycin resistance gene is a well-known and well characterised marker for positive selection that is routinely used in the field. Expression of the neomycin resistance gene can be selected for with the antibiotic G418.
As indicated above, in some embodiments of vectors of the invention the marker for positive selection is flanked by, typically identical, site-specific recombination sites which are recognisable by a site-specific recombinase enzyme (i.e. two, typically identical, site-specific recombination sites may be present, one positioned 5′ to the marker for positive selection and one positioned 3′ to the marker for positive selection). Preferably, the site-specific recombination sites are loxP sites. A loxP site nucleotide sequence is set forth herein as SEQ ID NO:7. When exposed to an appropriate site-specific recombinase enzyme, e.g. Cre recombinase in the case of LoxP sites, the recombinase can recognise recombining site-specific recombination sites and mediate the deletion of the nucleotide sequence that is located between the two site-specific recombination sites, e.g. in this case the marker for positive selection.
In some embodiments, the vector of the invention comprises, in order from 5′ to 3′, (i) a 5′-homology arm, (ii) a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C (preferably a nucleotide sequence encoding human Protein C); (iii) a first part of a 3′-homology arm; (iv) a first site-specific recombination site; (v) a marker for positive selection; (vi) a second site-specific recombination site and (vii) a second part of a 3′-homology arm. Preferably, elements (i)-(vii) are as described elsewhere herein).
Thus, in preferred embodiments, the vector of the invention comprises, in order from 5′ to 3′, (i) a 5′-homology arm comprising (or consisting of) a nucleotide sequence of SEQ ID NO:2; (ii) a nucleotide sequence encoding human Protein C; (iii) a first part of a 3′-homology arm said first part comprising (or consisting of) a nucleotide sequence of SEQ ID NO:3; (iv) a first loxP recombination site comprising (or consisting of) a nucleotide sequence of SEQ ID NO:7; (v) a marker for positive selection that is the neomycin resistance gene (Ned); (vi) a second loxP recombination site comprising (or consisting of) a nucleotide sequence of SEQ ID NO:7; and (vii) a second part of a 3′-homology arm said second part comprising (or consisting of) a nucleotide sequence of SEQ ID NO:4.
In one preferred embodiment, the vector comprises a nucleotide sequence of SEQ ID NO:9. SEQ ID NO:9 is a nucleotide sequence present in the vector used in the Example section herein to generate targeted mouse embryonic stem ES cells in accordance with the invention, which in turn were used to generate genetically modified mice in accordance with the invention. SEQ ID NO:9 includes the 5′-homology arm, the nucleotide sequence encoding human Protein C, the first part of the 3′-homology arm, the loxP flanked neomycin resistance gene (Ned), and the second part of the 3′-homology arm.
As indicated above, in some embodiments a negative selection marker is additionally present in the vector. A negative selection marker is a nucleotide sequence (or gene) which, when expressed in cells, encodes a protein that leads to cell death (or is toxic to the cells). The nucleotide sequence (or gene) encoding the negative selection marker is located in the vector outside of the homology arms, i.e. located either 5′ with respect to the 5′-homology arm or 3′- with respect to the 3′-homology arm.
In some embodiments, the negative selection marker is a nucleotide sequence encoding a toxin such as diptheria toxin A (DTA) or a nucleotide sequence encoding thymidine kinase (preferably a nucleotide sequence encoding DTA). During homologous recombination, nucleotide sequences outside of the homology arms are typically lost, but if the vector is randomly integrated (non-homologously recombined) into the genome the negative selection marker is typically retained and expressed. In such a case (unlike if the correct homologous recombination event has occurred), the negative selection marker is typically transcribed and translated which creates a selective disadvantage for clones with non-homologous (random) integration. The negative selection marker DTA is toxic to cells by inhibiting protein synthesis and thus cells expressing DTA are typically eliminated. The negative selection marker thymidine kinase (TK) renders cells in which it expressed sensitive to thymidine analogues. Thus, cells expressing TK can be eliminated (or selected against) by culturing the cells in the presence of a thymidine analogue.
In a some embodiments, a vector of the invention comprises, in order from 5′ to 3′, (i) a marker for negative selection; (ii) a 5′-homology arm, (iii) a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C (preferably a nucleotide sequence encoding human Protein C); (iv) a first part of a 3′-homology arm, (v) a first site-specific recombination site, (vi) a marker for positive selection, (vii) a second site-specific recombination site and (viii) a second part of a 3′-homology arm. Preferably, elements (i)-(viii) are as described elsewhere herein.
Thus, in preferred embodiments, a vector of the invention comprises, in order from 5′ to 3′, (i) a marker for negative selection; (ii) a 5′-homology arm comprising (or consisting of) a nucleotide sequence of SEQ ID NO:2; (iii) a nucleotide sequence encoding human Protein C; (iv) a first part of a 3′-homology arm said first part comprising (or consisting of) a nucleotide sequence of SEQ ID NO:3, (v) a first loxP recombination site comprising (or consisting of) a nucleotide sequence of SEQ ID NO:7; (vi) a marker for positive selection that is the neomycin resistance gene (Ned); (vii) a second loxP recombination site comprising (or consisting of) a nucleotide sequence of SEQ ID NO:7; and (viii) a second part of a 3′-homology arm said second part comprising (or consisting of) a nucleotide sequence of SEQ ID NO:4.
In one embodiment, the vector comprises a nucleotide sequence of SEQ ID NO:9 and, located either 5′ thereto or 3′ thereto (preferably located 5′ thereto), a marker for negative selection (e.g. as described herein).
In addition to the components of the vector described above that are important for targeting (i.e. generating a “knock-in” allele), the vector also typically comprises a vector backbone nucleotide sequence. The substantive components of the vector can be readily assembled and cloned into a vector backbone using routine methods in the art (as for example described in Green and Sambrook., 2012, Molecular Cloning: A Laboratory Manual, 4th Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. and other laboratory textbooks). Methods for preparing vectors for gene targeting are well-known in the art and any suitable method may be used.
In some embodiments, the vector comprises (or consists of) a nucleotide sequence of SEQ ID NO:1, or a sequence substantially homologous thereto. Substantially homologous sequences are described elsewhere herein. Preferably, if the vector has such a substantially homologous sequence, the alteration in nucleotide sequence is outside of the region of the targeting vector that is defined by SEQ ID NO:9. In a preferred embodiment, the vector comprises (or consists of) a nucleotide sequence of SEQ ID NO:1. The vector may be circular or linearized.
Vectors are typically constructed (or assembled) as circular nucleic acid (DNA) molecules and are then linearized before use. Thus, in some embodiments, the vector is a linearized vector. Linearizing is typically done using a restriction enzyme which recognises and cuts at a restriction site that is located outside of the substantive components of the vector (e.g. is located in the vector backbone), e.g. located 5′ with respect to the 5′-homology arm and located 3′ with respect to the 3′-homology arm. In some embodiments, the vector has been linearized using the restriction enzyme NotI. For example, in some embodiments, a vector of the present invention is a linearized vector produced by linearizing (e.g. with NotI) a circular vector comprising (or consisting of) a nucleotide sequence of SEQ ID NO:1.
The term “nucleic acid molecule” as used herein refers to a sequence of nucleoside or nucleotide monomers composed of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof. The nucleic acid sequences of the present invention may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. Deoxyribonucleic acid sequences (DNA) sequences are preferred. The sequences may also contain modified bases. The nucleic acid molecules may be double stranded or single stranded, preferably double stranded. The nucleic acid molecules may be wholly or partially synthetic or recombinant.
The nucleic acid molecules of the invention may be “isolated” or “purified”. The term “isolated” or “purified” typically refers to a nucleic acid that is substantially free of cellular material or other nucleic acids from the source from which it is derived or produced.
In another aspect, the present invention provides a non-human pluripotent stem cell that has been transfected with a vector of the invention.
In another aspect, the present invention provides a method for producing (or generating) a non-human pluripotent stem cell in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent stem cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In some embodiments, the method for producing (or generating) a non-human pluripotent stem cell comprises the steps of:
(i) transfecting non-human pluripotent stem cells with a vector of the invention; and
(ii) selecting one or more transfected non-human pluripotent stem cells of (i) to identify one or more non-human pluripotent stem cell clones in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent stem cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
Such methods for producing non-human pluripotent stem cells are in vitro methods.
Preferably, the non-human pluripotent stem cells are of a species of non-human animal described elsewhere herein. In some embodiments, the non-human pluripotent stem cells are non-human embryonic stem (ES) cells. Preferably, the non-human pluripotent stem cells are mouse pluripotent stem cells. Particularly preferably, the non-human pluripotent stem cells are mouse embryonic stem (ES) cells. In some embodiments, the mouse embryonic stem (ES) cells are C57BL/6 ES cells.
Step (i) of said method involves transfecting non-human pluripotent stem cells with a vector of the invention. Typically, the vector is linearized (e.g. with NotI) prior to transfection. Transfection may be performed by any suitable means and the skilled person is familiar with appropriate and standard transfection protocols. For example, transfection may be done by electroporation, lipofection, nucleofection, or the like. In some embodiments, electroporation is preferred.
Step (ii) of said method involves selecting one or more transfected non-human pluripotent stem cells of (i) in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent cell has been replaced by a nucleotide sequence encoding human Protein C (or a functional fragment or functional variant thereof). The selecting of step (ii) typically comprises analysing for (or screening for) the presence or absence in the transfected non-human pluripotent stem cells of the desired homologous recombination event (or desired targeting event), i.e. analysing (directly and/or indirectly) for the presence or absence in the genome of the non-human pluripotent stem cell of a Protein C allele that has been correctly targeted with the targeting vector.
Typically, the selecting step of (ii) comprises selecting one or more transfected non-human pluripotent stem cells on the basis of the expression of a marker for positive selection (a marker for positive selection is typically provided by the targeting vector). Preferably, the marker for positive selection is the neomycin resistance gene (Ned) and selection agent is G418 (e.g. 200 μg/ml). Typically, G418 resistant clones are picked and amplified (e.g. in a 96 well plate).
Typically, the selecting step also comprises, in addition to selection on the basis of the expression of a marker for positive selection, the analysis of genomic DNA to determine whether or not the desired homologous recombination event has occurred. This analysis of genomic DNA may be done using a PCR (polymerase chain reaction)-based method and/or by Southern blotting and/or DNA sequencing. Preferably, PCR-based and Southern blotting analysis is done.
In some embodiments, the PCR-based method comprises performing a PCR reaction in which the template DNA is genomic DNA isolated from the transfected non-human pluripotent stem cells under investigation (i.e. the potentially targeted non-human pluripotent stem cells) and PCR primers are designed such a PCR product of an expected size is produced if the desired homologous recombination event has occurred. An exemplary and preferred PCR-based method is described in the Example section herein (and is depicted in
In some embodiments, Southern blotting is performed to determine (or confirm) whether or not the desired homologous recombination event (targeting event) has occurred. In such analysis, genomic DNA isolated from the transfected non-human pluripotent stem cells under investigation (i.e. the potentially targeted non-human pluripotent stem cells) is digested with a restriction enzyme (e.g. Bsu36I or EcoNI). In such Southern blotting a probe is used which is capable of hybridising to a DNA fragment of the digested genomic DNA, that fragment being expected to be of a certain (pre-determined) size if the desired homologous recombination event has occurred. In some embodiments, the probe is capable of hybridising to a fragment of the digested genomic DNA that comprises the (or part of the) positive selection marker (e.g. a probe capable of hybridising to the (or part of the) neomycin resistance gene). An exemplary and preferred Southern blotting method is described in the Example section herein (and is depicted in
In a particularly preferred embodiment, the selecting of one or more transfected non-human pluripotent stem cells to identify one or more non-human pluripotent cell clones in accordance with step (ii) of the above method is as described in the Example section herein.
Typically, a non-human pluripotent stem cell produced in accordance with the invention is heterozygous for a human Protein C allele in accordance with the invention.
In another aspect, the present invention provides a non-human pluripotent stem cell produced by a method of the invention.
In another aspect, the present invention also provides the use of a vector of the invention for the generation of a non-human pluripotent stem cell in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In another aspect, the present invention provides a method of producing (or generating) a genetically modified non-human animal of the invention. Embodiments of other aspects of the invention described herein apply, mutatis mutandis, to this aspect of the invention.
In some embodiments, said method comprises:
(i) providing a non-human pluripotent stem cell in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent stem cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C; and
(ii) generating a genetically modified non-human animal from said non-human pluripotent stem cell.
Methods of generating genetically modified non-human animals from non-human pluripotent stem cells are well-known in the art.
In some embodiments, the non-human pluripotent stem cell of (i) is produced by a method for producing a non-human pluripotent stem cell in accordance with the present invention.
In some embodiments, the non-human pluripotent stem cell is a non-human pluripotent stem cell in which one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human pluripotent cell has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in some embodiments, the non-human pluripotent stem cell is heterozygous for a human Protein C allele in accordance with the invention.
Typically and preferably, the step of generating a genetically modified non-human animal of step (ii) comprises
In some embodiments, in step (a) the one or more non-human pluripotent stem cells and the pre-implantation embryo are each derived from non-human animal strains having different coat colours (i.e. the one or more non-human pluripotent stem cells is derived from a non-human animal having one coat colour and the pre-implantation embryo is derived from a non-human animal of the same species having a different coat colour).
In some embodiments, in step (a) the introduction of one or more non-human pluripotent stem cells into a pre-implantation embryo is done by injection.
In some embodiments, in step (c) the identification of founder animals is done by identifying those of the female animal's offspring that exhibit coat colour chimerism. Such coat colour chimeras are founder animals (F0 generation).
In some embodiments, in step (d) a founder animal is typically mated with a non-founder animal of the same species. In some embodiments, in step (d), if the non-human pluripotent stem cells of (a) comprise a marker for positive selection flanked by site-specific recombination sites (e.g. loxP sites), the founder animal may be mated with an animal that expresses a site-specific recombinase enzyme (e.g. Cre recombinase) in order to remove the marker for positive selection.
Typically, in step (d), the identifying of offspring comprises determining the genotype of the offspring to identify offspring that have a genome in which at least one copy of the endogenous nucleotide sequence encoding Protein C has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Put another way, in step (d) the identifying of offspring comprises identifying those offspring that result from germline transmission of genomic DNA of the non-human pluripotent stem cell of (a), said genomic DNA comprising a human Protein C allele in accordance with the invention.
In some embodiments, determining the genotype of the offspring is performed by a PCR-based method and/or by DNA sequencing. Suitable methods are known in the art. A preferred PCR-based method and DNA sequencing method are described in the Example section herein, and represent preferred embodiments.
In some embodiments, the genetically modified non-human animal produced by the method of the invention is an animal in which one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said animal has been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in some embodiments, the non-human animal is heterozygous for a human Protein C allele (i.e. it has one copy of a human Protein C allele in accordance with the invention and one endogenous non-human Protein C allele). Identifying an animal as such a heterozygote may be done by a PCR-based method, for example as described in the Example section herein.
In some embodiments, the genetically modified non-human animal produced by the method of the invention is an animal in which both copies of the endogenous nucleotide sequence encoding Protein C in the genome of said animal have been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in some embodiments, the non-human animal is homozygous for a human Protein C allele (i.e. it has two copies of a human Protein C allele in accordance with the invention and no endogenous non-human Protein C allele). Identifying an animal as such a homozygote may be done by a PCR-based method, for example as described in the Example section herein.
Producing non-human animals that are homozygous for a human Protein C allele in accordance with the invention may be done by mating together non-human animals that are heterozygous for a human Protein C allele in accordance with the invention and identifying (e.g. by PCR-based genotyping) amongst the offspring of such a mating those animals that are homozygous for a human Protein C allele in accordance with the invention.
Thus, in some embodiments, the method of producing (or generating) a genetically modified non-human animal of the invention further comprises steps of identifying non-human animals produced as being heterozygous for a human Protein C allele in accordance with the invention, mating such heterozygous non-human animals together, and identifying offspring from said mating that are homozygous for a human Protein C allele in accordance with the invention. Such a method thereby produces a genetically modified non-human animal in accordance with the invention that is homozygous for a human Protein C allele in accordance with the invention. Thus, in some embodiments, the invention provides a method for producing a genetically modified non-human animal in which both copies of the endogenous nucleotide sequence encoding Protein C in the genome of said non-human animal have been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C.
In some embodiments, the method of producing (or generating) a genetically modified non-human animal of the invention further comprises one or more steps to introduce (or make) one or more additional genetic modifications into the genome of the non-human animal (i.e. additional to the replacement of an endogenous nucleotide sequence encoding Protein C by a nucleotide sequence encoding human Protein C or fragment or variant thereof).
In some embodiments, the further genetic modification is a modification that results in the down regulation or inactivation (or renders the animal deficient in or devoid of) of one or more other (i.e. non-Protein C) genes. For example, the further genetic modification may be a knock-out of one or more other genes. In some embodiments, the other gene is a gene encoding a blood clotting factor (e.g. one or more blood clotting factors may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor VIII (e.g. Factor VIII may additionally be knocked-out). In some embodiments, the other gene is a gene encoding Factor IX (e.g. Factor IX may additionally be knocked-out). In some embodiments, there may be further genetic modifications in the genes encoding Factor VIII and Factor IX (e.g. Factor VIII and Factor IX may additionally be knocked-out).
The introduction of one or more further genetic modifications (e.g. gene knock-outs) may be done by any appropriate means, e.g. by mating a genetically modified non-human animal of the present invention with an animal of the same species which comprises the desired further genetic modification(s) (e.g. which has the desired gene knocked-out). Thus, in some embodiments, methods may further comprise mating a genetically modified non-human animal of the invention with an animal of the same species which has Factor VIII and/or Factor IX knocked out. Appropriate mating strategies can be readily devised to produce and select (e.g. by genotyping such as by PCR-based genotyping) non-human animals which comprise a genetic modification in accordance with the invention (i.e. the replacement of at least one endogenous nucleotide sequence encoding Protein C by a nucleotide sequence encoding human Protein C or fragment or variant thereof) and an additional genetic modification (such as a knock-out of Factor VIII and/or Factor IX).
In some embodiments, a non-human animal of the invention additionally comprises a knock-out of Factor VIII. A mating strategy to produce and select (identify) such non-human animals is described in the Example section herein and represents a preferred mating strategy in accordance with the invention.
Non-human animals (e.g. mice) comprising a genetic modification (e.g. knock-out) of one or more additional genes (e.g. to be used in matings as described herein) may be produced by any suitable means (e.g. by preparing non-human embryonic stem cells with the desired genetic modification and generating genetically modified non-human animals therefrom). However, in many cases, as is the case for a Factor VIII knock-out mouse, non-human animals comprising a desired genetic modification (e.g. a gene knock-out) are commercially available (e.g. from The Jackson Laboratory, US).
A particularly preferred method of producing (or generating) a genetically modified mouse of the invention is described in the Example section herein.
In another aspect, the present invention provides a genetically modified non-human animal produced by a method of producing of the invention.
In another aspect, the present invention provides a method of testing one or more agents (e.g. candidate therapeutic agents or drugs), said method comprising
Such methods of testing may alternatively be considered methods of screening or investigating. Such methods of testing (or screening or investigating) would typically be considered pre-clinical methods. Accordingly, although these methods aim to identify the potential for an agent to be used in therapy, such testing methods would not themselves be considered to be therapeutic methods. Thus, in some embodiments, the methods of testing in accordance with the present invention are not methods of therapeutic treatment.
In preferred embodiments of methods of testing of the invention, in the genetically modified non-human animal two (i.e. both) copies of the endogenous nucleotide sequence encoding Protein C in the genome of the non-human animal have been replaced by a nucleotide sequence encoding human Protein C, encoding a functional fragment of human Protein C or encoding a functional variant of human Protein C. Thus, in preferred embodiments, the genetically modified non-human animal is homozygous for a human Protein C allele in accordance with the invention.
In some embodiments, methods of testing in accordance with the invention further comprise a step of assessing (or determining or evaluating) whether or not (or the extent to which) there has been an alteration in one or more physiological activities (or functions) in the animal, preferably an alteration in one or more therapeutically relevant physiological activities (or functions). The relevant physiological activity to be assessed may depend on the particular therapy of interest (i.e. depend on the particular disease or condition for which a potentially useful therapeutic agent is being tested), e.g. as discussed elsewhere herein.
In some embodiments, the alteration in one or more physiological activities (or functions) in the animal is an alteration as compared to an appropriate control.
A “control” physiological activity or “control level” of a physiological activity may be the physiological activity in a control animal or a control population of animals. Appropriate controls for use in the methods of the invention would be readily identified by a person skilled in the art. For example, a control physiological activity (or control physiological activity level) may be the physiological activity in a genetically modified non-human animal of the invention of the same species that has not had the agent (test agent) administered. Other controls may include the physiological activity (or control physiological activity level) in a wild-type (or normal) non-human animal of the same species. The control level may correspond to the level of the same (or equivalent) physiological activity in an appropriate control animal. Alternatively, the control level may correspond to the level of the physiological activity in question in the same individual genetically modified non-human animal measured at an earlier time point (e.g. comparison with a “baseline” level in that animal). Control levels may also be referred to as “normal” levels or “reference” levels. The control level may be a discrete figure or a range. Although the control level for comparison could be derived by testing an appropriate control animal or population of control animals, the testing methods of the invention would not necessarily involve carrying out active tests on control animals as part of a method of the present invention, but may involve a comparison with a control (or control level) which had been determined previously from a control animal (or control population of animals) and was known to the person carrying out a method of the invention.
The alteration may be an increase or a decrease (increase in the physiological activity or a decrease in the physiological activity). An alteration in a physiological activity (e.g. in comparison to a control) may indicate that the agent is (or may be) therapeutically useful.
Any measurable (or detectable) alteration (increase or decrease as the case may be) in the physiological activity may be indicative that the agent may be therapeutically useful. To be indicative that the agent may be therapeutically useful, the physiological activity is preferably significantly altered, compared to a control. More preferably, the significantly altered levels are statistically significant, preferably with a p-value of <0.05.
In some embodiments, an alteration (an increase or decrease as the case may be) in the physiological activity (or level of physiological activity) of ≥2%, ≥3%, ≥5%, ≥10%, ≥25%, ≥50%, ≥75%, ≥100%, ≥200%, ≥300%, ≥400%, ≥500%, ≥600%, ≥700%, ≥800%, ≥900% or ≥1,000% compared to the physiological activity (or level of physiological activity) in an appropriate control indicates that the agent may be therapeutically useful.
As indicated above, methods of testing agents in accordance with the present invention may identify the potential for the use of such agents in therapy (e.g. human therapy). In preferred embodiments, the therapy (or potential therapy) is therapy (or potential therapy) of a disease or condition associated with Protein C or APC (or the Protein C or APC pathway). In some embodiments, the therapy is therapy of a disease or condition characterised by an aberrant, or abnormal or dysregulated molecular mechanism, molecular pathway or cascade wherein Protein C or APC (or the Protein C pathway or APC pathway) is a component of (or associated with, or a part of, or involved in the regulation of) said molecular mechanism, molecular pathway or cascade. In some embodiments, the therapy is therapy of a pathophysiological condition involving Protein C or APC (or the Protein C pathway or APC pathway).
In some embodiments, the therapy is therapy of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting.
In some embodiments, the therapy is therapy of a disease or condition characterized by inflammation and/or apoptosis (e.g. aberrant or unwanted or excessive inflammation and/or apoptosis), e.g. sepsis.
In preferred embodiments, the agents to be tested include agents that potentially alter the level and/or functional activity of human Protein C or APC (or the Protein C or APC pathway). Such agents may include agents from natural sources, such as a cell extracts, and agents from synthetic sources such as chemical compound libraries, or biological libraries such as antibody or peptide libraries.
In preferred embodiments, the agents to be tested include agents that bind to (or specifically bind to or directly bind to or interact with) human protein C or human APC. Agents may include chemical compounds (e.g. small molecule chemical compounds) and antibodies (or antigen binding fragments thereof) that bind to (or specifically bind to) human Protein C or human APC.
In preferred embodiments, the agent to be tested is an antibody or antigen binding fragment thereof. In particularly preferred embodiments, the agent to be tested is an antibody that binds to (or specifically binds to) human protein C or human APC. Preferably, such antibodies are monoclonal antibodies.
In other embodiments, the agent to be tested is a nucleic acid-based molecule (e.g. an RNAi, shRNA or siRNA molecule) that reduces or inhibits the translation of human Protein C mRNA.
The agents to be tested may include antagonists (or inhibitors) and/or agonists (or potentiators) of human Protein C or human APC (or the human Protein C or human APC pathway). Whether to test agents that are antagonists (or that are potentially antagonists) of human Protein C or human APC or whether to screen agents that are agonists (or that are potentially agonists) of human Protein C or human APC may depend on the particular disease or condition for which a potentially useful therapeutic agent is being screened, tested or investigated (or sought).
For example, in embodiments in which a method of testing agents (e.g. candidate therapeutic agents or drugs) is to identify their potential use in haemophilia (e.g. haemophilia A or haemophilia B) therapy (or therapy of other diseases characterized by impaired clotting), testing antagonists (or inhibitors) of human Protein C or human APC is typically preferred. Such antagonists (or inhibitors) may include antibodies (antagonistic antibodies) that bind to (or specifically bind to) human protein C or human APC (or antigen binding fragments of such antibodies), or serine protease inhibitors (e.g. small molecule serine protease inhibitors). Antibodies, or antigen binding fragments thereof, that bind to (or specifically bind to) human Protein C or human APC are preferred. Monoclonal antibodies are particularly preferred.
By way of another example, in embodiments in which a method of testing agents (e.g. candidate therapeutic agents or drugs) is to identify their potential use in the therapy of a disease or condition characterized by inflammation and/or apoptosis (e.g. sepsis), screening for agonists of human Protein C or human APC is typically preferred.
As typically and preferably the agents being tested are agents that potentially alter the level and/or functional activity of human Protein C or human APC (or the Protein C or APC pathway), typically the physiological activity (or function) assessed is a physiological activity (or function) that is associated with Protein C or APC, or associated with the Protein C or APC pathway. Thus, in some embodiments the physiological activity (or function) assessed is a physiological activity (or function) that is associated with Protein C or APC, or associated with the Protein C or APC pathway. A physiological activity associated with Protein C or APC may be any physiological activity characterised by the involvement of a molecular mechanism or signalling cascade in which Protein C or APC is a component. In some embodiments, biomarkers, such as the expression (or level of expression) of certain genes or proteins may be used as a readout of physiological activity.
Blood clotting is a preferred physiological activity. Such a physiological activity may be the time taken for bleeding to cease following the initiation of bleeding, or the rate of bleeding following the initiation of bleeding, or the amount of bleeding following the initiation of bleeding.
Thus, in some embodiments, the physiological activity (or function) is an activity associated with blood clotting (or bleeding). In some embodiments, the physiological activity (or function) is the time taken for blood clotting to occur, e.g. the time taken for bleeding cessation (or cessation of blood leakage) to occur following the initiation of bleeding, e.g. following a bleeding injury. In some embodiments, for example when the genetically modified non-human animal is a mouse, the physiological activity (or function) is the time take for the cessation of bleeding (or blood leakage) following tail transection (e.g. transection of the distal tail).
In some embodiments, the time taken for bleeding cessation may be determined by administering an agent to be tested to a genetically modified non-human animal of the invention, then initiating (or inducing) bleeding in said animal and measuring the time taken for bleeding to cease. If the agent (test agent) provides an improvement in bleeding cessation, e.g. a reduction in the time taken for bleeding to cease, as compared to a control, that is typically indicative that the agent may be useful for the treatment of haemophilia or other disease or condition characterised by impaired blood clotting. The control may be as discussed elsewhere herein.
In some embodiments, the time taken for bleeding cessation may be determined by (i) administering an agent to be tested to a genetically modified mouse (e.g. an anesthetized mouse) of the present invention (e.g. administering by injection into the orbital vein), optionally the tail of the mouse being immersed in saline (e.g. at 37° C.), (ii) transecting the distal tail of the mouse (e.g. at 4 mm) to initiate bleeding (e.g. arterial and venous bleeding) and optionally immersing the tail in saline (e.g. at 37° C.), (iii) measuring the bleeding time following tail transection (typically bleeding time is the length of time following transection at which blood leakage has ceased for at least 1 minute). In some embodiments, the transection of (ii) is performed about 5 minutes after the administration of the agent of (i). A particularly preferred method for determining bleeding cessation is described in the Example section herein.
In some other embodiments, the time taken for bleeding cessation may be determined by initiating (or inducing) bleeding in a genetically modified non-human animal of the invention, administering an agent to be tested to said animal and measuring the time taken for bleeding to cease. If the agent provides an improvement in bleeding cessation, e.g. a reduction in the time taken for bleeding to cease, in comparison to a control, that is typically indicative that the agent may be useful for the treatment of haemophilia or other disease or condition characterised by impaired blood clotting.
In some embodiments, when the physiological activity (or function) being assessed is an activity associated with blood clotting (or bleeding), e.g. as discussed above, the method of testing in accordance with the invention is to identify the potential use of the agent in the therapy of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease or condition characterized by impaired clotting.
As indicated above, if the agent provides an improvement in bleeding cessation, e.g. a reduction in the time taken for bleeding to cease, in comparison to a control, that is typically indicative that the agent may be useful for the treatment of haemophilia or other disease or condition characterised by impaired blood clotting. In some embodiments, a reduction of ≥2%, ≥3%, ≥5%, ≥10%, ≥25%, ≥50%, ≥75%, ≥80%, ≥90% or even 100% in the time taken for bleeding to cease in comparison to a control is indicative that the agent may be therapeutically useful in the therapy (e.g. human therapy) of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting. In some embodiments, a reduction of at least 30 seconds, at least 1 minute, at least 2 minutes, at least 3 minutes, at least 4 minutes, at least 5 minutes, at least 10 minutes, at least 15 minutes, at least 30 minutes or at least 1 hour in the time taken for bleeding to cease, in comparison to a control, is indicative that the agent may be therapeutically useful in the therapy (e.g. human therapy) of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting. Suitable controls are discussed elsewhere herein.
In some embodiments of methods of testing agents to identify potentially useful agents for the therapy of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting, the genetically modified non-human animal may be deficient in (e.g. devoid of) one more clotting factors, such as Factor VIII or Factor IX (e.g. the genetically modified non-human animal may have one or more genes encoding clotting factors, such as Factor VIII and/or Factor IX, knocked-out). Thus, in some embodiments, the genetically modified non-human animal used in such methods may comprise one or more additional genetic modifications that render them deficient in (e.g. devoid of) Factor VIII and/or Factor IX, e.g. they may additionally have the gene encoding Factor VIII and/or the gene encoding Factor IX knocked-out, or the Factor VIII and/or Factor IX gene or protein may be otherwise down-regulated or inactivated. Deficiency in Factor VIII is characteristic of haemophilia A. Deficiency in Factor IX is characteristic of haemophilia B.
In some embodiments, the effect of an agent being tested on a physiological activity (or function) (e.g. an activity associated with blood clotting such as the time taken for bleeding to cease as discussed above) may be compared to the effect of a blood clotting factor (such as Factor VIII or Factor IX) on the same physiological activity. In some embodiments, the clotting factor (e.g. Factor VIII or Factor IX) may be a human clotting factor. The clotting factor may be a recombinant clotting factor (e.g. a recombinant human clotting factor) or a clotting factor purified from plasma (e.g. from human plasma). Thus, in some embodiments a control physiological activity is the physiological activity in a genetically modified non-human animal of the invention to which a blood clotting factor (e.g. Factor VIII or IX) has been administered (e.g. a positive control).
In some embodiments, when the control physiological activity is the physiological activity in a genetically modified non-human animal of the invention to which a blood clotting factor (such as Factor VIII or IX) has been administered, if the agent being tested, exhibits ≥2%, ≥3%, ≥5%, ≥10%, ≥25%, ≥50%, ≥75%, ≥80%, ≥90% or even ≥100% of the activity of the administered blood clotting factor (e.g. Factor VIII or IX or other procoagulant clotting factor), e.g. as determined by (or in terms of) the time taken for bleeding to cease, then that may indicate that the agent is useful for the therapy (e.g. human therapy) of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting.
In some embodiments, if the physiological activity (e.g. the time taken for bleeding cessation) in a genetically modified non-human animal of the invention to which a test agent being tested has been administered is ≥2%, ≥3%, ≥5%, ≥10%, ≥25%, ≥50%, ≥75%, ≥80%, ≥90% or even ≥100% of the same physiological activity in a control non-human animal of the same species to which a blood clotting factor such as Factor VIII or Factor IX (or other procoagulant clotting factor) has been administered, then that may indicate that the agent is useful for therapy (e.g. human therapy) of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting.
In some embodiments, if the genetically modified non-human animal is deficient in Factor VIII, the physiological activity in a genetically modified non-human animal of the invention to which Factor VIII has been administered may be used as a control. In some embodiments, if the genetically modified non-human animal is deficient in Factor IX, the physiological activity in a genetically modified non-human animal of the invention to which Factor IX has been administered may be used as a control.
As discussed above, in some embodiments of methods of testing agents in accordance with the invention the purpose is to identify agents that are potentially useful in the therapy of a disease or condition that is characterized by inflammation and/or apoptosis (e.g. aberrant or unwanted or excessive inflammation and/or apoptosis), e.g. sepsis.
In some such embodiments, the physiological activity (or function) assessed is inflammation or apoptosis. Any suitable means for assessing inflammation or apoptosis may be used and the skilled person is familiar with appropriate methods and assays (e.g. by challenging the animal with lipopolysaccharide (LPS) or E. coli and assessing the effect of an agent being tested thereon). If inflammation and/or apoptosis is decreased in a genetically modified non-human animal that has been treated with an agent being tested, as compared to a control, that is typically indicative that the agent may be useful for the treatment of a disease or condition that is characterized by inflammation and/or apoptosis (e.g. aberrant or unwanted or excessive inflammation and/or apoptosis), e.g. sepsis. The control may be as discussed elsewhere herein.
As indicated above, methods of testing can aim to identify the potential use of agents in therapy (e.g. human therapy). Therapy includes treatment and prophylaxis.
In another aspect, the present invention provides an agent identified by a method of testing of the invention. The present invention also provides a method of treating a disease or condition in a subject (preferably a human), e.g. a disease or condition as defined elsewhere herein, said method comprising administering a therapeutically effective amount of an agent identified by a method of testing of the invention. The present invention also provides an agent identified by a method of testing of the invention for use in therapy (preferably human therapy), preferably said therapy is of a disease or condition defined elsewhere herein.
In another aspect, the invention provides the use of a genetically modified non-human animal of the invention for drug screening or drug testing. In another aspect, the present invention provides the use of a genetically modified non-human animal of the invention for the screening or testing of candidate therapeutic agents, typically candidate therapeutic agents that target (or bind to) human Protein C or human APC. Examples of such agents are discussed elsewhere herein.
Such testing would typically be considered experimental testing, or pre-clinical testing. The agents (or drugs) would typically be candidate therapeutic agents, but their use in testing would not typically be considered a therapeutic use.
In another aspect, the invention provides the use of a genetically modified non-human animal of the invention (e.g. mouse) as an experimental animal model. In some embodiments, the experimental model (e.g. mouse model) is an experimental model of a disease or condition, preferably a disease or condition associated with Protein C or APC (or the Protein C or APC pathway). In some embodiments, the disease or condition is a disease or condition characterised by an aberrant, or abnormal or dysregulated molecular mechanism, molecular pathway or cascade wherein Protein C or APC is a component of (or associated with, or a part of, or involved in the regulation of) said molecular mechanism, molecular pathway or cascade. In some embodiments, the disease or condition is a pathophysiological condition involving Protein C or APC (or the Protein C or APC pathway).
In some embodiments, the experimental model is an experimental model (e.g. mouse model) of a bleeding disorder such as haemophilia (e.g. haemophilia A or haemophilia B) or other disease characterized by impaired clotting.
In some embodiments, the experimental model is an experimental model (e.g. mouse model) of a disease or condition characterized by inflammation and/or apoptosis (e.g. aberrant or unwanted or excessive inflammation and/or apoptosis), e.g. sepsis.
In some embodiments in which a genetically modified non-human animal of the invention is used as an experimental model animal, the animal may comprise one or more further genetic modifications (e.g. may comprise a knock-out of one or more other genes).
In some embodiments in which a genetically modified non-human animal of the invention is used as an experimental model, for example of haemophilia (or other bleeding disorder or disease or condition characterized impaired clotting), the animal may be deficient in (e.g. devoid of) one more clotting factors. In some embodiments in which a genetically modified non-human animal of the invention is used as an experimental model, for example of haemophilia (or other bleeding disorder or disease or condition characterized impaired clotting), the animal may be deficient in (e.g. devoid of) Factor VIII and/or Factor IX. Thus, in some embodiments in which a genetically modified non-human animal of the invention is used as an experimental model, for example of haemophilia, the genetically modified non-human animal may comprise one or more additional genetic modifications to render them deficient in (e.g. devoid of) Factor VIII and/or Factor IX, e.g. they may additionally have the gene encoding Factor VIII and/or the gene encoding Factor IX knocked-out, or the Factor VIII and/or Factor IX gene or protein may be otherwise down-regulated or inactivated.
In some other embodiments in which a genetically modified non-human animal of the invention is used as an experimental model of a bleeding disorder the animal may be deficient in (e.g. devoid of) Factor X and/or Factor XI. Thus, in some embodiments in which a genetically modified non-human animal of the invention is used as an experimental model the genetically modified non-human animal may comprise one or more additional genetic modifications to render them deficient in (e.g. devoid of) Factor X and/or Factor XI, e.g. they may additionally have the gene encoding Factor X and/or the gene encoding Factor XI knocked-out, or the Factor X and/or Factor XI gene or protein may be otherwise down-regulated or inactivated.
Where the terms “comprise”, “comprises”, “comprising”, “has” or “having”, or other equivalent terms are used herein, then in some more specific embodiments these terms include the term “consists of”, “consisting of”, “consisting essentially of”, or “consists essentially of”, or other equivalent terms.
As used throughout this application, the terms “a” and “an” are used in the sense that they mean “at least one”, “at least a first”, “one or more” or “a plurality” of the referenced components or steps, except in instances wherein an upper limit is thereafter specifically stated.
List of Nucleotide and Amino Acid Sequences Disclosed Herein and their Sequence Identifiers (SEQ ID NOs)
All nucleotide sequences are recited herein 5′ to 3′ in line with convention in this technical field.
1741 GGGAAC CCTGGC AGCTTG CAAAAC GCAAAG GGCTAC GGCTGC ATCGCT CTTTTC CAGACT
1801 TCTCAG CTGGGA GCTTCT GGCAGT TTTCCC GAGTCA CTCCTT TCTCTC ACTAGC TCACAA
1861 AGTGGC CAGCTG AGTCAG AAGCCT CCTTCT AGTACA GGCCTG CCTCCC ACCAAC GCCATC
1921 AATCAG GACAAG TAAGGA AGACTT CTGAGT CGCCCC CCCCCC CCACCG GTCAAA TAGAGG
1981 GGACAT CTTATC ACTGAT GGCATC CTAGAT TGGTGA TATATG TAATTA TTTTTG AGTGTG
2041 CTACCC ACGAAC AAGCTA TATCTG TTTATG GTTGCT GTTGTT TTGGTT TTTGTT TTCTTT
2101 TAAGGT TCTCAT CCCTCA GCCACT GCGGGC AAAAAT GAGACC ACATTT GCCAAT AAGTTT
2161 GAACAC GCTCAA CCCTCT CTTTCT CCCTCC CTTTCT GATAGA CAATTC CTTCGG TAGGCA
2221 GAGGTG AGCAAT GGGCAC ACGGAG CCTTCC AGAGCT GGGATC AGAAAA CCTCTT GTTTGT
2281 TTGTCT GGGGAG AGGGAG GTTCGG CACCAA GGGCTA AGCAAA TATTTG CGGTTA TGGATT
2341 AACCTG ACTCCC AGACTG ACATGG CGCTAC CTGGAC GAAATT GCAGTT TCTCCT TGGCCC
2401 ACGCCT GTAAGT CCCCCT CATTGC AAGACT GTGAAG GACTGT GGAGGG AGGGGA GGGGAG
2461 GAAAGT CCAGCT GGGAGG AAGGTG ACGTTC TTGAGC TAAGGC TCTCCA GGCAGA CTGAAA
2521 TGTGGG GCCAAG GAAAAT GAGCGC CCAAAC TCTATC TGGACC AAGGCG TGGGTT CCCTAC
2581 AATCCA GGTGAC CATCTC GACACA TGAGAT TTTGTG GATCAA GTGGAC AGCAGT CAAAGG
2641 GTTCCC TATGAT CAGGAA CCATCC TCAGAG CAATCT TGAAAC CCAGAA CCCCAC TACTCC
2701 CCTCTG CCCTGT TCTCTA AGGTGG ACTCTA CAATTC CGGAAG CCAGCA AAGCCG AAGAGT
2761 GAGGCC AGGAGG GGCTGT GCAGCT GGGATA GGCGGG CCTGCC CACCTG GTCTGG GGGACA
2821 CTAGAG GCCTTG TGGTTT GACTAC TGGTTG GGGGCA GGGGTT AAGGTT CCAGAG TTGGGG
2881 CCACAT AGGCTT GGCCTT GAAGCC AAACTC TGCCCT CCTCTT AGGTGT AGGCTT GTGACA
2941 AGCCGC GTATCT CCTCCA AGCCTT TGGGTC CCTTCC CATGAA ATGGAG GTGAGA ATATTC
3001 ATGCCT TCCTCT TTTAAC AGTGAT CAGTGT GTGTGT GTGTGT GTGTGT GTGTGT GTGTGT
3061 GTGTGT GTGTGT GTGTGT GTGTGG TGTAGA GTGTGG TTTCTG GTGTTC AGGGTT GAACCC
3121 AGAATC TTAAAC ATGCCA AGTACG TTCTTT CCTACT GAACTG CAACCC TCCAGT ATCCTG
3181 TACTTG TTGTTT GTTTGT TTGTTT GTTTGT TTGTTC GGAAGC ACCTGT GGTGGC ACACAC
3241 TTACAA TCCTAG TGCTAG AGAGCA GAAACA AGTGGA TCCCTT GGGCTT GCTGGC TGGCCA
3301 GCCTAC GTGATG AGTTTC AGGCAG TGAGAG ACCTTG TCCCAA ACAATA AGGTGG AAGTAA
3361 GCCATG ATGGCA TACCCC TTTAGA GCTAGT ACTCGA GAGGCA GAAGCA GGTGGA GTTTAA
3421 GACCAG CCTGGT CTACAT AGAAGT TCCAGG ATAGCC AAAAAG TACCCA AGGCCA TCCAAA
3481 AAAACA AAAACA AAACAA AACCTG GAGGGA AAAAAA AAACCA GACAAT GCCTGG GGAAGG
3541 ATGAAG GACAGT CAGTCA GATTAT CCCTGG TCAACA CGTGTG CACAAA TCTGTG CACACA
3601 AGAAAG AGCTTC ACATGG GTTACT ATTTGT TTTCCA ACAACT CATTTT TAAGCC CCCACT
3661 CTCTTT CTCTGT TTTTAA AAAAGG TTTATT TATTTT ATGTAT ATGAGT ACATTA TTGCTC
3721 TCTTCA GACACA CCAGAA AAGGAC ATAAGA TTCCAT TACAGA TGGTTG TGAGCC ACCATG
3781 TGGTTG CTGGAA TTTGAA CTCAGG TCCTCT GGAAGA GCAGTC GGTGCT CTTAAC CACTGA
3901 AAATGA CAGAAC TGAGGC ACGGAG CACGTA AACATC TTGTTA AATACC TCTCTC TCTCTC
3961 TCTCTC TCCCCA GTAGGA AATGGA ATTTGC CCCAGG CAATGA CTTTTT TTTTTT TTTTTT
4021 TGCTTT CATGTA CCTAGA GTAAGC CCAGCT CTAAAG GCCACG AGATTG TCTGTC TGTGGA
4081 CCGTGG TGTACC CCACTC CCAGAC CCAGCT TCCACA CAGACA ATGAGC TCACAA ACGTCC
4141 TTTACT CCCTTC CTTCCT TGCTTG CTCTGT GTGTGT GTGTGT GTGTGT GTGTGT GTGTTA
4201 AGAGAT CAACCT CAGACA TTTTCT TTAGGA GCTATT TACCTT GCTTTT TGAGAC AGGGCC
4261 TCCGGA TGGCCT GGAGCT AGTCAC CTGGAG CTGGTC AAGCAG GCTAGG GTGGCT GGCCTA
4321 AGCAAT CCACAG GATCTG CTTATC TCTGCC TCCCCA GTCCTG GGATTA CAAGAA ACGCCT
4381 CAGACA CCTAGA TTTCTG TTTTAA TTTTCT ATGGGT TCTGGG GATCTT TCTTAA GTCTTC
4441 AAGTAT GCACGG AAAGGG CTTTAT TGACTA AGATAT CTCCCC TGCTCA GGAATG GCCCTT
4501 TCATTC TACTTT GGAGGG AGCTGG GGGTGG GGCGGG GAGCAG CTCAGC TGTGTG TATCCT
6001 TGCTCA CCTCTG GACCCT AGAAGT CACTCT TGGAGT AAGGCT GGGCTA GTGAGT ACCAAG
6061 ACAGAG GACATT AAAGGA GCATGC AACAAA CATA
CC TCCCCG AGTACC TGTCTG TCTTTT
6121 CATCCT TTTTAT GGGCTA TTCTGG GGGAAA GTAACA TTAATT GAGCAT GCACTA CACACC
6181 AAGTCT ATGAAA AGAACC TGCTTA ACTCCC AAAGCA GTTGTG TAGAAG ATCTAG TGGGAT
6241 CTGAGC TGATAT CACTTC TGGGGG TGAGTG GAGGAG ATTGAT TTAGAG AAAGGA ATTTTT
6301 TTAGAA GTTACT GTAAGA GACTAA TAGAGC CTTTCT CAGGGC CTTGGA AAGAGC CCGTGC
6361 TAGTTA CATCAG AAAAGC TTGCCA GTGACC AGTGGC CAGTGA GACTCA GAATGG CCATGT
6421 GGTGGA GCCAGG ATTCAA ACCAAG GTCACA CTCCCA AACTCA GCTGCT TCTCTT CTTTAT
6481 TATCCC TGGGTG TGTGCT GGTGTG TGTGTG CGCGCG TGGGTG TGTGGG TGGATA CATGCA
6541 TGTGTG TGTGTG TGTGTG TGTGTG TGTGTG TGTGTG TGTGTG TTATAT GTTTGG AGACCA
6601 GAGGAC AACTTC GTTTCT CAACAC CATCCA CTTGTT TTGTTT TGTGTT TTGTTT TGTTTG
6661 TTGACA CAGGGT CTCTCA CTGTCC TGAAAT CTACCC AGTAGG CTAGGC TGGCTG GCTACC
6721 AAACCC CACCCC ACCCTG GCTTTG ACAAGT GGAGAC AGAAGA CCAGTA GTCCAC TGGAGA
6781 TGTGAC CAGATG CCCAGA AGGTGC TCCTCA TGGTGC CCTACA GTTTTG TTGAGG AGTCTG
6841 TTTAAT AATGCA GCTGGG TGCAGT GGCAGC ACCTGT AGCCCC CAATAC TGAGGC AGCATT
10861 TCCCTT AAAAAA AACAAA AGAGAA GGAAGA AGGACG AAGTAG AATGTG GAGGAC AAACAG
10921 GGGAGA GAGGGG GAAAGA AAGGGA GGGAAT TGTCTT AGAGTT TTACGG CTGTGC ACAGAC
10981 ACCATG ATCAAG GTAACT CTTGTA AGGATA ACATTT AGTTGG GGCTGG CTTACA GGTTCA
11041 GAAGTT CAGTCC ATTATC ATCAAG GCAGGA ACATGG CAGCAT TCAAGG CAGACA TGGTGC
11101 AGGAGG AGCTGA GAGTTC TACATC TTCATC TGAAGA TTTCTA GTAGAA TACTGG CTTCCA
11161 GGCAGC TAGGAT GAGGGT CTTAAA GCCCAC ACCCAG TGACAC ACCTAC TCCAAC AGGGCC
11221 ACACCT CCTAAT CATGCC ACTCCC TGGGCT GAGCAT ATAGAA ACCATC ACAGAG TCTAAC
11281 TAGTGT GGCCCA TCCTGC ACCCAT GGAAGA CCATCA CTGGGG CATAGA CAACCT CCAGAG
11341 CCCACC CTGACA GTTCCT GTCTCT GCCTTC TCCAGC AGTCAC CAGTTT CAAATA GCTCCT
11401 CAAGGA CAGATG GGGCCT TGTGAG CTTCAC CCCGCT GCAGGC TGGAAT GCGCCA CCTTTA
11461 ATCCCA GCACTT GGAAGG CAGAGG CAGGCA GATTTC TGAGTT CGAGGC CAGCCT AGTCTA
11521 CAGAGT GAGTTC CAGGAC AGCCAG GGCGAT ACAGAG AAACCC TGTCTC AAAAAA CAAAAC
11581 AAAACA AAACGA TAGAAA AGAGCA AAGTGA CCTTGG GCTATG GATGGG ATGGAC CATCGG
11641 GCACTG GGTTGG GAAGCT GAACTG GTCCAG ATGCCC AGAGCC CAGAGC TCTCTC CTCAGC
11701 AGTTCA TAACCT GGGGTG TTGCCA CAGCAC ACACAG CAAGGT TAGTTC TGCTGG TTGTCG
11761 GGACTT AGGGTA GGAGGA GTAGAA GCCTGC TACTGA TTCTGT CTCTCT CTGTTT CTCTCT
11821 CCTCCC TCCCTC CCTCCT TCCCTC CCTCCC TCCCTC TTCTTC TTCTTC TCATCC TCCTCC
11881 CTCTTC CTCTTC TTCCTC CACCTC CCCACC CCTTAT TTTGAT ACAGGG TTTCTC TGTGTA
11941 TCCCTG GCTGTC CTGGAA CTCACT CTGTAG CCCAGG TGGGCC TCGAAC TCTCAG CCTCAG
12001 TCCCCA GAATGC TGAGAA CACAGG TCTGAG TGATCA CTGATG GCTAAA AGTTGG GATTAC
12061 ATTGTT GTTGCT TGTTTG TTTATT CTTTTG TACATG GGACCC AAATAC AAATAG TAGCCT
12121 CAACAA TAAACA CGGGAT AAGTTG CTGCTC TGCTTT AGGGTC TCCCTG ACCTCT GTTTTT
12181 TTGTTT TTTGTT TTTGGT ATGTTT TGTTTT CTGTTG TTGTTG TTATCA TGTCTA TAAATC
12241 TATCTT CCTTCC TCCCTC CTTCCT TCCCTT CCTACT TCCCTC TCTTTC TTCATC CCTCCC
12301 TTCCCC CTACTC TCTTTC ACCCCC AGATAG GAAGCA AGCATG ATAAAA ACGTGT GGTGTT
12361 TTCCTT TTTATG TAGAGA GTACTG TGTAGT GAGTGT TATCCT ATGGGT GCTGCC ATTCTG
12421 CTGTAT GTTACC TGCTGT ATGTTA TACCAA CCTAGA TGGTGG TGAACT CACATG GTTGCT
12481 TCCATC TTGGTG AGGTTA CCAGCC AAGATG TCTGCC CTCCAC ATGATT GCCTCC ATCTTG
12541 GTGAGG TAAATG TTTAAT AAAGTA ACAAAA CAAGAC ATTAAA AACAAA CATTCC AGCACA
12601 AAATCT TCTTGA GATTAG AGACAT AATAGG AAGTCA GGTGAG GTCATA CAGGCC ATTAAT
12661 CCCATC ACTTGG GGAACA GAGGCA GGTAGA ACTTTG AATTGA AGGCAG GTATAT TTAGTG
12721 ATTTCC AGGGCT ATGTAG AGAGGC CCCTGA CCCAAC TAATAA GTAAAC AGGAAG ATAAAT
12781 AAATAT AATGAA CTTAGA ATAAAA CAAAGA AAGGAA GAAACA AGGGAA GGCAGT GCTGGG
12841 GGCCTG GCTTAT GGTGGA TGGGGG AATTCT GTGCTA GGGTGC CTGAAA CTCTGG GCTCCA
12901 TCCTCT GTAGTG CATAAA CTCTTT GGTACG TTAGCC CCTGTC TGTAAC AAGGAG CTGTCC
12961 ACGGTT GCAGTA CTGCCT TTCCCA TCTCAG CTGCCC CTCAGG AGCTGT CCACAG TGGCGA
13021 CACTTT TTCATC CTCAGC CTACAG CTTTAG GGAAAC ACCACT GCAGGG GCTGTC CCAAAG
13081 GTGCTG TCCACA GAGGCA GCACCT TCTCTG TGGTCT CACCCC TCCAGA CACCCC CCAGCA
13141 GCCCCA CAGGGA TGGCAC CTCAGT AAAAGC CAACTG TGGCCA GAGAAG TCTTCC TACCCT
13201 AACTCA TAGACT CGATGC AGGGAA AACAGG GTGAAA AAAAGC CACCAA GCCCTG AGCTCC
13261 CCCCAG CTCAGG ACTTAA AATCTC ATCAAT CCTCAC TATGGA AATCTC TGCCTT GAGAAG
13321 CTCTGC CCCCTC ATAAAT CCTATA TAAGAA CTGTCC CTTTGT CCAGTT CCCTGC CATCCG
13381 CTCCCA GGAGCA GAGGGC AGTTAT CCCTGG ATTCAT CCCTCC ACACCC TGGACC TGCCAA
13441 TAAACC TTTCTT GAGATT TCATGC TTCCTG TGATTC TCAGTG GAAGAA GCCAAG AAGAAA
13501 AGAACC AAAGAG AGGGAG CCAGGC TGAGGC TCCTGA GTTCTT CAGCTC AGCTGT GGATAC
13561 CTGTGA TGGTTT GTATAT GCTCTG TCCAGG GAATGG CATGAT TAGAAG GTGTGG CCCTGT
13621 TGAAGT AGGTGT GTCACT GTGGGT GTGGGC TATAAG ACCCTC ATCTTA ACTGCA TGGAAG
13681 TCATTC TTCCAC TGGCAG CCTTCA GATGAA AATGTA GAACTC TCAGCT CCTCCT GCACCA
13741 TGCCTG CCTAGA TGCTGC CCTGCT CCCACC TTGATG ATAATG GACTGA ACCTCT GAACCT
13801 GTAAGC CAGCCC CAATTA AATGTT GTTCTT TATAAG TCTTGC CTTGGT TGTGGT GTCTGT
13861 TCACAG CAGTAA AACCAT GACTAA GACAAT ATCTTC TACTTG GAGCTG CAACAA CTCTGC
13921 TGAGGA GGCTTC CTCTCA GAGCTA TATGGT TCCTGG TATCTG TAAAAT TCCCTT CTATTG
13981 GGACAC TTTCCA ACCTCA GATCTG TGTGGT TCCTGG CCCCTG TGTCTC GGGATG CCCTTC
14041 CATTAG AACAGC TTCTCC CCTCAG AGCTGC ATGGTT CCTGGA CTTCTG AGTCCC AGGAGA
14101 CCCTTC CATCTG AGCAGA AACACT TACAGG AGCAGA GTCCTC CAACAC CACGGT TTTGTT
14161 TTGAAA GACCAA GACCAA CCCTCA GGAGGT TTCTGG CAAAGG CAGATT CTAGGT GCACCT
14221 GGAGGA GACCTA TAGTGC AGGACC ATCCGT CGTAGG TTGCTA GGCACC AATGGG CAAAGG
14281 TAGGGA AGAAAT CTTACC AGAAGA TTCTAT TCCATT CCATTC TCCTCA CAATGT AAGAGC
14341 CAAAGT TAACCT CTAAGG CCCAAG AACAAG GTAACT CTCCAG AATGCT GGGAGA TGTAGT
14401 TCTTGG GTAACA ACAAGC CATGTT CTCGCC CTAAAC AAGTTT GTTTGA ATCAAC TACACT
14461 GAATGT ACTTGA TCATAT GTAGGA GAGAGA AGATTG ATTCTA GTTCAG GGTTTC AGGCTA
14521 TTTCAG TCCACC ATGATG GGAAAG GCATGA CATTGT TTATGA CAGTAA GAGCAT GTAGCA
14581 GAGGAT CCTCAC ATCACA ACAGGC CGAAAT GCAGAG GACAGT GCAACC AGAGGA CAGTCT
14641 GTAACT TTCCAA GTCCCT CTTCTA GTGGGT TGCTTC CACCAC CTCTCA GGTGGT GCTACA
14701 GCTCAG GAACAA TTGAGA TGTGTG ATGAAG GGCAGG TACTCA ACTGTG GCTGTA TTGTAT
14761 CCTTTT ATAGTT GTCCTC TGTGTG TTGAGC TATGTG CGAGAT TCTCAG GTCATC GGAGTA
14821 CCTGTT TTACTT TGGCAG GCATAG GAGACT CCTGAG AACTCT GCCTGA CATCCT TGCCAG
14881 CCCAAG CTTTGG TTTAGT GTGTGC AGTATC ACTCTT GGGTCT TATCTG CATATC CCTGAT
14941 GGCCCA TCAAGA TGTGTG CGGCCG CGTACC AGCTTT TGTTCC CTTTAG TGAGGG TTAATT
In SEQ ID NO:1 the solid underlined portions represent the homology arms. The portions of the homology arms shown with a double solid underline correspond to untranslated regions (UTRs), more specifically the 5′ UTR that is part of exon 2 of mouse Protein C and the 3′ UTR that is part of exon 9 of mouse Protein C. The portion shown in bold italics represents the nucleotide sequence coding for human Protein C. The portions represent loxP sites.
The invention will now be further described in the following non-limiting Example with reference to the following drawings.
Human Protein C Constitutive Knock-in Mouse Model
Targeting Vector
A targeting vector for generating a knock-in of human protein C into the mouse (C57BL/6) protein C locus was constructed. The nucleotide sequence of the targeting vector is set forth in SEQ ID NO:1.
The mouse protein C gene (NCBI Reference Sequence: NM_001042767.3) is located on mouse chromosome 18. Nine exons have been identified, with the ATG start codon in exon 2 and TAG stop codon in exon 9.
The human protein C gene (NCBI Reference Sequence: NM_000312.3) is located on human chromosome 2. Nine exons have been identified, with the ATG start codon in exon 2 and TAG stop codon in exon 9.
For the knock-in model mouse described herein, the region from ATG start codon to TAG stop codon of mouse protein C was replaced with the coding sequence of human protein C. Thus, the targeting vector includes the coding sequence of human protein C flanked by homology arms for targeting to the mouse protein C locus to achieve targeted replacement of the nucleotide sequence encoding mouse protein C with the human protein C coding sequence.
The targeting vector further comprises, positioned 3′ with respect to the human protein C coding sequence (human PROC CDS), a Neo cassette (Ned) flanked by loxP sites. Expression of the Neo cassette can be selected for using the antibiotic G418. The targeting vector further comprises, positioned outside of the homology arms and positioned 5′ with respect to the 5′ end of the 5′ homology arm, a DTA (diphtheria toxin A) negative selection marker.
Mouse genomic fragments containing homology arms (HAs) were amplified from BAC clone by using high fidelity Taq DNA polymerase, and were sequentially assembled into a targeting vector together with site-specific (loxP) recombination sites and selection markers, and the human Protein C coding sequence.
A schematic depiction of the wildtype mouse Protein C allele, the targeting vector, the targeted allele, and the constitutive knock-in (KI) allele (after Neo′ deletion) is set forth in
A further depiction of the targeting vector is provided in
The targeting vector was digested by restriction enzymes for confirmation purposes. The results of these confirmatory restriction enzyme digests are shown in
Correct construction of the targeting vector was also confirmed by nucleic acid sequencing.
Generation of Human Protein C Constitutive Knock-in Mouse Embryonic Stem (ES) Cells
The human protein C targeting construct (SEQ ID NO:1) was linearized by restriction digestion with NotI, followed by phenol/chloroform extraction and ethanol precipitation. The linearized vector was transfected into C57BL/6 ES cells according to standard electroporation procedures. The transfected ES cells were subject to G418 selection (200 μg/mL) 24 hours post electroporation. 564 G418 resistant clones were picked and amplified in 96-well plates. Two copies of 96-well plates were made, one copy was frozen down and stored at −80° C. and the other copy of the 96-well plates was used for DNA isolation and subsequence PCR screening for homologous recombination. The PCR screening identified 16 potential targeted clones, from among which 12 were expanded and further characterized by Southern blot analysis. Eight of the twelve expanded clones were confirmed to be correctly targeted. The PCR screening and Southern blot analysis is described in more detail below.
The regions shown in
3′ Arm PCR
Primers for 3′Arm PCR:
Expected PCR Product:
Wildtype: None
Targeted: ˜4.5 kb
Reaction Mix:
Cycling Condition:
The results of the 3′ arm PCR screening are shown in
The potentially targeted clones were further screened by PCR for the presence of the knock-in (KI) site.
Primers for KI PCR:
Expected PCR Product:
Wildtype: None
Targeted: 380 bp
Reaction Mix:
Cycling Condition:
The results of the KI PCR screening are shown in
Based on the PCR screening, samples 2H7, 3B2, 3E2, 3C4, 3D8, 3C11, 4B2, 4A4, 4H3, 4G10, 4A12, 5C5, 5G6, 5G8, 6H3 and 6B5 were shown as potentially targeted ES clones.
Positive clones (2H7, 4A12, 4B2, 3C4, 3C11, 5G6, 4A4, 3B2, 6B5, 3D8, 5G8 and 4G10) from PCR screening were expanded and further characterized by Southern blot analysis. The Southern strategy is shown in
Expected Fragment Sizes for Southern Blot:
Neo Probe (containing 5′ arm)—10.37 kb-Bsu36I
Neo Probe (containing 3′ arm)—11.39 kb-EcoNI
Eight of the twelve clones (2H7, 4B2, 3C4, 3C11, 4A4, 3D8, 5G8 and 4G10) were confirmed to be correctly targeted by Southern blot analysis. The results of the Southern blot analysis are shown in
Generation of Human Protein C Constitutive Knock-in Mice
Targeted ES cell clone 3C4 was injected into C57BL/6 albino embryos, which were then re-implanted into CD-1 pseudo-pregnant females. Founder animals were identified by their coat color, their germline transmission was confirmed by breeding with C57BL/6 females and subsequent genotyping of the offspring. Cre mouse (i.e. a Cre recombinase expressing mouse) was used to mate with F0 (founder animals) to generate F1 mice in which the Neo′ cassette that was flanked by loxP sites was deleted. Four male and two female heterozygous targeted mice were generated from clone 3C4. Further details of the mouse genotyping strategy are provided below:
The regions shown in
K11 PCR
Primers for KI1 PCR:
Expected PCR Product:
Wildtype: N.A.
Targeted: 380 bp
Reaction Mix:
Cycling Condition:
K12 PCR
Primers for KI2 PCR:
Expected PCR Product:
Wildtype: N.A.
Targeted: 324 bp
Reaction Mix:
Cycling Condition:
Neo Deletion PCR
Primers for Neo Deletion PCR:
Expected PCR Product:
Wildtype: 298 bp
Targeted: 230 bp
Reaction Mix:
Cycling Condition:
Results of the Mouse Genotyping PCRs:
Seven pups (1 #, 2 #, 3 #, 4 #, 5 #, 6 # and 7 #) from clone 3C4 were identified positive (i.e. positive for the presence of the constitutive human protein C knock-in (KI) allele) by PCR screening for KI1, KI2 and Neo deletion as described above, the positive pups were reconfirmed by PCR screening for Neo deletion. The PCR results for the Neo deletion PCR confirmed that these pups were heterozygous for the constitutive human protein C knock-in (KI) allele. The Neo deletion PCR also confirms that the 3C4 ES cells were heterozygous for the targeted allele. Note: one mouse (6 #) died. The results of the mouse PCR-based genotyping are shown in
PCR amplification from mouse DNA was also done using primers F1 and R3 and the PCR amplified fragment (which includes the coding sequence (CDS) of human Protein C and also mouse UTR sequence) was sequenced and no mutations were found. An image of the PCR amplified fragments run on an electrophoretic gel is presented in
Primers for Sequencing PCR:
Expected PCR Product:
Wildtype: N.A.
Product Size: 2795 bp
Reaction Mix:
Cycling Condition:
Generating Homozygous Human Protein C Knock-in Mice and Generation of Further Mice Having the Human Protein C Knock-in and Also Factor VIII Deficiency and Generation of Further Mice Having the Human Protein C Knock-in and Also Factor IX Deficiency
Expected PCR Product: Wildtype: None, Targeted: 380 bp. This hproC primer pair recognizes the human protein C knock-in allele but does not recognize the wildtype (i.e. non-targeted) mouse protein C allele.
Expected PCR Product: 280 bp from wildtype mice and heterozygous human protein C mice. This mproC primer pair can detect the mouse protein C allele (but not the human protein C targeted allele) and thus can detect wildtype mice, heterozygous human protein C knock-in mice, but not homozygous human protein C knock-in mice.
For the avoidance of doubt, the genotype hproC+/+ means that the mouse is homozygous for the human Protein C coding sequence (i.e. homozygous for the human Protein C “knock-in” allele). As the targeting vector results in the replacement of the mouse Protein C coding sequence with the human Protein C coding sequence it thus follows that mice of the genotype hproC+/+ do not comprise the mouse Protein C coding sequence. The genotype hproC+/− means that the mouse is heterozygous for the human Protein C coding sequence (i.e. heterozygous for the human Protein C “knock-in”). Thus, a mouse with the genotype hproC+/− comprises the coding sequence for human Protein C (human Protein C “knock-in”) and the coding sequence for mouse Protein C. The genotype hproC−/− means that the mouse is homozygous for mouse Protein C and does not comprise the human Protein C coding sequence (i.e. does not comprise the human Protein C “knock-in”).
Expected PCR Product: WT (+) F8=620 bp, Mutant (−) F8=420 bp
For the avoidance of doubt, the F8-WT-Forward and F8-Mut-Forward primers discriminate between the wildtype Factor VIII (F8) allele and the mutant Factor VIII (F8) allele.
Expected PCR Product: WT(+)F9=620 bp, Mutant(−)F9=420 bp
For the avoidance of doubt, the F9-WT and F9-Mut primers discriminate between the wildtype Factor IX (F9) allele and the mutant Factor IX (F9) allele. Note: The F9 (factor IX) gene is located on X chromosome in mouse. Therefore, male heterozygous F9 deficient mice do not have wildtype F9 gene and are equivalent to homozygous F9 deficient mice for mating purposes.
25%
25%
19%
25%
19%
Hemophilia Mouse Models
For hemophilia A model, 8 to 10-week-old mice including WT mice, factor VIII deficient mice (F8−/−) and human protein C knockin and factor VIII deficient double mutant mice (hproC+/+, F8−/−) anesthetized using 80 mg/kg sodium pentobarbital i.p. were placed on their abdomen with the tail immersed in 37° C. saline. The distal tail of mice was transected at 4 mm (severe injury), and the bleeding was arterial and venous. Human factor VIII was injected into an orbital vein 5 min before the tail was transected. Controls were also performed in which no Human Factor VIII was injected. For hemophilia B model, the same procedures were conducted except that factor IX deficient mice (F9−/−), human protein C knockin and factor IX deficient double mutant mice (hproC+/+, F9−/−), and human factor IX were used. Bleeding time was measured following the tail-tip transection and immediate immersion of the tail in 10 ml of saline at 37° C. Bleeding time was set at cessation of blood leakage for at least 1 min. After 15 min, the tail was removed from the saline and the bleeding time measure was ended.
Humanized protein C knockin mice were generated by targeted inactivation of the murine protein C gene with a human protein C expression cassette, as described above. The mice (hproC+/+) are viable and able to cross with mouse disease models such as coagulation factor VIII deficient (F8−/−) or factor IX deficient (F9−/−) mice and such models are useful to study the functions of human protein C and activated protein C in mice in vivo.
Human protein C knockin and factor VIII deficient (hproC+/+, F8−/−) or humanized protein C knockin and factor IX deficient (hproC+/+, F9−/−) double mutant mice were generated as described above. These mice appear to be normal and healthy without challenges. If the double mutant hproC+/+F8−/− or double mutant hproC+/+F9−/− mice are challenged by tail cut bleeding, the prolonged bleeding time is comparable to the factor VIII deficient mice (F8−/−) or factor IX deficient mice (F9−/−), respectively. Prolonged bleeding time is the characteristic symptom of hemophilia. Human factor VIII or human factor IX could correct the prolonged bleeding time in factor VIII deficient mice or factor IX deficient mice, respectively, as well as in the respective double mutant mice. The results of the bleeding time study are shown in
That the bleeding characteristics observed with the double mutant mice (hproC+/+, F8−/−) or (hproC+/+, F9−/−) which express human Protein C (but not mouse protein C) are very consistent with the bleeding characteristics observed with the respective factor VIII deficient mice (F8−/−) or factor IX deficient mice (F9−/−) which express endogenous mouse Protein C (but do not contain the human Protein C knock-in) is desirable and advantageous as this indicates that the human Protein C can functionally complement for the mouse Protein C that has been removed in the double mutant mice. These results indicate that mice having the human Protein C knock-in will be useful models for studying haemophilia or other pathophysiological conditions involving protein C pathway. The double mutant models described in this example (hproC+/+, F8−/−; and hproC+/+, F9−/−) are such models. These models are invaluable and represent the first mouse model for in vivo testing therapeutic candidate agents targeting human protein C or APC.
The double mutant mouse model (hproC+/+, F8−/−) described herein is useful as a model for testing potential candidate therapeutic agents targeting human protein C or APC. This double mutant mouse model is particularly useful as Factor VIII deficiency is characteristic of haemophilia A (classic haemophilia) and thus these mice provide a model of the situation in haemophilia A subjects. Without wishing to be bound by theory, blood clotting in Factor VIII deficient subjects (e.g. haemophilia A sufferers) can still occur, albeit at a much slower rate. Although Factor VIII is a major target of APC, in a Factor VIII deficient subject APC can still exert anticoagulant activity via its inhibitory effect on activated Factor V (fVa). Activated Factor V is essential for clotting and is a major target of APC. Without wishing to be bound by theory, targeting (inhibiting) human Protein C/APC in a Factor VIII deficient animal (e.g. a haemophilia sufferer characterised by a Factor VIII deficiency) can improve clotting by reducing the inhibition of activated Factor V (fVa).
The double mutant mouse model (hproC+/+, F9−/−) described herein is useful as a model for testing potential candidate therapeutic agents targeting human protein C or APC. This double mutant mouse model is particularly useful as Factor IX deficiency is characteristic of haemophilia B and thus these mice provide a model of the situation in haemophilia B subjects.
Other hproC+/+ knock-in mice of the invention (i.e. other than the hproC+/+F8−/− or hproC+/+F9−/− double mutants described in the present Example) would also be useful mouse models for studying human Protein C (or human activated Protein C, APC) in vivo and identifying potential Protein C/APC targeting therapeutic agents. For example, hproC+/+ knock-in mice that are also deficient in Factor X or Factor XI would represent a useful mouse model as it would represent the situation in human patients who are deficient in Factor X or Factor XI.
In the context of Factor VIII and/or Factor IX deficiency or absence (which characterise certain haemophilias), factor X could still be activated by tissue factor (TF) and activated Factor VII (fVIIa). In the presence of activated factor X (fXa) and activated Factor V (fVa) (which as mentioned above is essential for clotting), prothrombin could be activated into thrombin to initiate clotting. Without wishing to be bound by theory, targeting (inhibiting) human Protein C/APC, e.g. in Factor VIII and/or Factor IX deficient animals, could improve clotting by reducing the inhibition of activated Factor V (fVa).
hproC+/+ knock-in mice that do not contain any further genetic modifications (e.g. no knockouts of other genes) would also be useful mouse models for studying human Protein C/APC activity in vivo and testing potential candidate therapeutic agents targeting human protein C or APC, not only with a view to identifying potential haemophilia therapies, but also therapeutic agents useful in other pathophysiological conditions involving the protein C pathway.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201911027061.6 | Oct 2019 | CN | national |
| 1915689 | Oct 2019 | GB | national |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5831141 | Lubon et al. | Nov 1998 | A |
| 6066778 | Ginsburg et al. | May 2000 | A |
| 20050125851 | Whitsett et al. | Jun 2005 | A1 |
| 20120082987 | Sasgary et al. | Apr 2012 | A1 |
| 20120192298 | Weinstein | Jul 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 102690803 | Sep 2012 | CN |
| 107929719 | Apr 2018 | CN |
| 0 319 312 | Jun 1989 | EP |
| 0 319 312 | Sep 1990 | EP |
| WO 1997020043 | Jun 1997 | WO |
| WO 2002096947 | Dec 2002 | WO |
| WO 2004056310 | Jul 2004 | WO |
| WO 2017044864 | Mar 2017 | WO |
| WO 2018022777 | Feb 2018 | WO |
| WO 2018023014 | Feb 2018 | WO |
| Entry |
|---|
| Jalbert et al (Inactivation of the Gene for Anticoagulant Protein C Causes Lethal Perinatal Consumptive Coagulopathy in Mice. J Clin. Invest., vol. 102, Oct. 1998. Cited in IDS dated Sep. 11, 2020) (Year: 1998). |
| Raife et al (Human Thrombomodulin Knockin Mice Reveal Differential Effects of Human Thrombomodulin on Thrombosis and Atherosclerosis. Arterioscler Thromb Vasc Biol., vol. 31, Nov. 2011. Cited in IDS dated Mar. 5, 2021) (Year: 2011). |
| NCBI Reference Sequence: NM_000312.3 (Year: 1985). |
| Foster et al (The nucleotide sequence of the gene for human protein C. PNAS, vol. 82, Jul. 1985). (Year: 1985). |
| Stagaard et al (Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. Blood Advances, vol. 2, Nov. 2018). (Year: 2018). |
| Bernard et al (Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. NEJM, vol. 344, Mar. 2001). (Year: 2001). |
| Lay et al (Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin. Invest., vol. 115, Jun. 2005. Cited in IDS dated Mar. 5, 2021) (Year: 2005). |
| Krisinger et al (Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma. FEBS, vol. 276, 2009. Cited in the IDS dated Sep. 11, 2020) (Year: 2009). |
| Barefield et al., Phosphorylation and function of cardiac myosin binding protein-C in health and disease; J Mol Cell Cardiol., 2010; 48(5):866-875. |
| Ranjan et al., Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells; Nat. Comm., 2017; 8(1):311. doi: 10.1038/s41467-017-00169-4. |
| Mosnier LO et al., The cryptoprotective protein C pathway, Blood 109:2161-3172 (2007). |
| Lay AJ et al., Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised . . . , J. Clin. Invest. 115:1552-1561 (2005). |
| Chan JCY et al., The Characterization of Mice with a Targeted Combined Deficiency of Protein C and Factor XI, Am. J. Pathol., 158:469-479 (2001). |
| Raife TJ et al, Human Thrombomodulin Knockin Mice Reveal Differential Effects of Human Thrombomodulin on Thrombosis . . . , Arterioscler. Throm. Vasc. Biol. 31:2509-2517 (2011). |
| Polderdijk et al., Targeting activated protein C to treat hemophilia, Curr. Opin. Hematol., 2017, 24: 446-452. |
| Krisinger et al., Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma, FEBS Journal, 2009, 276:6586-6602. |
| Jalbert et al., Inactivation of the Gene for Anticoagulant Protein C Causes Lethal Perinatal Consumptive Coagulopathy in Mice, J. Clin. Invest., 1998, 102(8): 1481-8. |
| Polderdijk and Huntington, Identification of serpins specific for activated protein C using a lysate-based screening assay, 2018, Scientific Reports, 8:8793. |
| Tada et al., Isolation and Characterization of a Mouse Protein C cDNA, J. Biochem. 111, 491-495 (1992). |
| Malm et al., Human activated protein C variants in a rat model of arterial thrombosis, Thrombosis Journal 2008, 6:16 doi:10.1186/1477-9560-6-16. |
| Xu et al., Endogenous activated protein C signaliing is critical to protection of mice from . . . septic shock, Journal of Thrombosis and Haemostasis, 7: 851-856 (2009). |
| Number | Date | Country | |
|---|---|---|---|
| 20210120789 A1 | Apr 2021 | US |
